Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
API is on sale here at 1.29. I never thought I would be able to buy it again at that price in my lifetime. You have got to take advantage of the old maxim buy 'em when nobody wants them and sell 'em when they can't get enough.
ENSV - hit as high as 1.01 - very thin - if it can get through the buck resistance, should attract value players that like the numbers and guidance provided by the company. Shale plays are in demand going forward.
INX.v, INXSF .36c...some corp events in the mobile area should be coning up over the next few weeks in addition to some new business apps that will be coming out. This is an undiscovered mobile play that is knocking the cover off the numbers and has a forecast for this FY that calls for min 25% growth in top line and further gains in bottom line. They did .05 pr sh net inc year end Dec for TTM PE of 7. My est for this year is .16-.18 per sh net inc and price by post 3rd qtr release 1.75-2.00+. MC
DTGI.ob, Digerati, has been investing in the cloud communications sector for the last 3 years, refining existing products and scvs and adding more. There are very few ways to play cloud communications in the small cap and microcap areas of the mkts and these guys have been in the comm biz for 17 years now.
There will be new cloud scvs and products rolled out next month.
I talked with mgmt and am convinced that these guys have the experience and mgmt team that can take them to the next few levels in the cloud comm niche. Again, there are almost NO microcap cloud comm co's out here, forecast for cloud computing to grow from $10B to $26B by 2014 and the small and mid sized businesses are the ones that need this tech the most as a cost saver. Also, Digerati has a leg up on both latin America and Mexico, a geogrphic area that is rapidly moving their corp's into the high tech area--huge growth coming there. Right now your risk is ten cents. That's how much you can lose. Conversely, 10 cents per sh invested now could return 5x-10x by year end, or more, if I am right about this company. I have followed them for years under ATSI before they changed their name a few mo ago. I think they can do it and I think Art Smith can get it done.
www.digerati-inc.com.
MC
SOTK waking up after long slumber-see chart. Dr. Coccio has unique company here with unique products and the numbers are starting to gain traction. Would most definitely look at this at 1.26 up .08. MC
NADVF-stock up .21 to 2.20-unique company-unique products-major clients lining up-could be a big play-buy and hold MC
NADVF-2.02-this was in Wall Street Journal 2 days ago-this contract with Hanes. Now they have Hanes and Levi Strauss...plus plus...
* BUSINESS
* APRIL 12, 2011
Hemmed In by Cotton, Hanes Eases Into Flax
Soaring Prices Lead Clothing Maker to Try an Alternative, Reflecting Urgency of Bringing Experimental Blends to Market
more in Business »
BY RACHEL DODES
Pressured by rising cotton prices, $4.3-billion-a-year apparel maker HanesBrands Inc. is developing new products made from a crop more often found in cereal: flax.
Last month, Naturally Advanced Technologies, a small Portland, Ore., maker of sustainable fabrics, said it signed a 10-year deal with Hanes to "commercialize" flax fiber. The fiber is typically discarded after the plant is harvested for its seeds and oil, which are used in health foods and industrial products.
Clothing companies are always searching for alternative fibers that will improve performance or cut costs. But the move by Hanes, known for its cotton-based undergarments and active ...
======================
NADVF, NAT.v-this just out with Levi Strauss-might be worth some major league dollars?? gpg
Naturally Advanced Technologies and Levi Strauss & Co. Enter Into Development Agreement For CRAiLAR Flax Fiber
prnewswire
Press Release Source: Naturally Advanced Technologies Inc. On Thursday April 14, 2011, 2:09 pm
PORTLAND, OR, April 14 /PRNewswire/ - Naturally Advanced Technologies Inc. (NAT) (OTCBB:NADVF.ob - News) (TSXV: NAT) today announced that it has entered into a short term CRAiLAR® Flax fiber development agreement with Levi Strauss & Co. beginning in April 2011 to support evaluation of processing CRAiLAR flax fiber in woven casual apparel products, specifically denim and non-denim, bottom and top weight fabrics.
"Levi's and Dockers are the quintessential denim and casual wear brands," said Ken Barker, CEO of NAT. "We are very excited to be working with a company like Levi's because it aligns with our broad strategic goal of identifying and partnering with the most important brands in categories upon which we believe we can make the greatest impact. I have great confidence in the ability of CRAiLAR to make a performance and economic impact for Levi's products."
Last month, the Company announced a 10-year purchasing agreement with Hanesbrands. This was the first commercialization agreement for its CRAiLAR flax fiber. Later that month, it announced a short term purchasing agreement with Georgia-Pacific to further evaluate the use of CRAiLAR in formed materials.
Naturally Advanced Technologies Inc.
Naturally Advanced Technologies Inc. develops renewable and environmentally sustainable biomass resources from flax, hemp and other bast fibers. The Company, through its wholly owned subsidiary, CRAiLAR® Fiber Technologies Inc., has developed proprietary technologies for production of bast fibers, cellulose pulp, and their resulting by-products in collaboration with Canada's National Research Council. CRAiLAR technology offers cost-effective and environmentally sustainable processing and production of natural, bast fibers resulting in increased performance characteristics for use in textile, industrial, energy, medical and composite material applications. The Company was founded in 1998 as a provider of environmentally friendly, socially responsible clothing. For more information, visit www.naturallyadvanced.com.
=======
NADVF-HERE IS ANOTHER CONTRACT WITH GEORGIA PACIFIC-SO THAT'S HANES, LEVI STRAUSS AND GEO PACIFIC-NOT TOO SHABBY-
Naturally Advanced Technologies Enters Into Short-Term CRAiLAR Flax Fiber Supply Agreement with Georgia-Pacific
prnewswire
Press Release Source: Naturally Advanced Technologies Inc. On Wednesday March 30, 2011, 1:29 pm EDT
PORTLAND, OR, March 30 /PRNewswire/ - Naturally Advanced Technologies Inc. (NAT) (OTCBB:NADVF.ob - News) (TSXV: NAT) today announced that it has entered into a short term CRAiLAR® Flax fiber supply agreement with Georgia-Pacific LLC (GP) starting in April 2011 to support evaluation of processing CRAiLAR flax fiber in formed materials.
The companies recently completed product-forming trials using CRAiLAR flax fibers, and the supply agreement allows for GP to purchase CRAiLAR flax fiber from NAT for additional product testing.
"We are excited to explore this aspect of possible development," said Ken Barker, CEO of NAT. "Our partnership with GP has proven to be a truly collaborative effort. We believe this step is important to identifying potential applications of our technology beyond those we are already exploring."
This is big for NAT,v, NADVF-just out
Agreement For CRAiLAR Flax Fiber 04/14 13:09 CDT Naturally Advanced Technologies and Levi Strauss & Co. Enter Into Development Agreement For CRAiLAR Flax Fiber PORTLAND, OR, April 14 PORTLAND, OR, April 14 /PRNewswire/ - Naturally Advanced Technologies Inc. (NAT) (OTCBB: NADVF) (TSXV: NAT) today announced that it has entered into a short term CRAiLAR(r) Flax fiber development agreement with Levi Strauss & Co. beginning in April 2011 to support evaluation of processing CRAiLAR flax fiber in woven casual apparel products, specifically denim and non-denim, bottom and top weight fabrics. "Levi's and Dockers are the quintessential denim and casual wear brands," said Ken Barker, CEO of NAT. "We are very excited to be working with a company like Levi's because it aligns with our broad strategic goal of identifying and partnering with the most important brands in categories upon which we believe we can make the greatest impact. I have great confidence in the ability of CRAiLAR to make a performance and economic impact for Levi's products." Last month, the Company announced a 10-year purchasing agreement with Hanesbrands. This was the first commercialization agreement for its CRAiLAR flax fiber. Later that month, it announced a short term purchasing agreement with Georgia-Pacific to further evaluate the use of CRAiLAR in formed materials. Naturally Advanced Technologies Inc. Naturally Advanced Technologies Inc. develops renewable and environmentally sustainable biomass resources from flax, hemp and other bast fibers. The Company, through its wholly owned subsidiary, CRAiLAR(r) Fiber Technologies Inc., has developed proprietary technologies for production of bast fibers, cellulose pulp, and their resulting by-products in collaboration with Canada'sNational Research Council. CRAiLAR technology offers cost-effective and environmentally sustainable processing and production of natural, bast fibers resulting in increased performance characteristics for use in textile, industrial, energy, medical and composite material applications. The Company was founded in 1998 as a provider of environmentally friendly, socially responsible clothing. For more information, visit www.naturallyadvanced.com . Neither the TSX Venture Exchange Inc. nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statement DisclaimerThis news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, are forward-looking statements. Forward-looking statements or information are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements or information and including, without limitation, risks and uncertainties relating to: any market interruptions that may delay the trading of the Company's shares, technological and operational challenges, needs for additional capital, changes in consumer preferences, market acceptance and technological changes, dependence on manufacturing and material supplies providers, international operations, competition, regulatory restrictions and the loss of key employees. In addition, the Company's business and operations are subject to the risks set forth in the Company's most recent Form 10-K, Form 10-Q and other SEC filings which are available through EDGAR atwww.sec.gov . These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements. SOURCE Naturally Advanced Technologies Inc. (TS:NADVF;NAT;)
INX.v, INXSF-you want to see year end earn report and forecast for much stronger FY this year. I do not know of a play in the mobile sector for business/commerce that presents a better buy at $.37c-I consider this a steal-read below and visit site-and my target for INX by end of 3rd qtr is $1.75-$2.00-6mo from now. MC
http://www.intouchinsight.com/
Managed Mobile Web Solutions for Industry
IN-TOUCH SURVEY SYSTEMS LTD. ANNOUNCES ANNUAL FINANCIAL RESULTS WITH SIGIFICANTLY IMPROVED PROFITS AND CASH FLOW
4/12/2011 4:17 PM - Canada NewsWire
OTTAWA, Apr 12, 2011 (Canada NewsWire via COMTEX News Network) --
In-Touch Survey Systems Ltd. ("In-Touch" TSX-Venture: INX) announces that revenue increased 8% to $5,893,125 in FY 2010 compared to $5,479,081 in FY 2009. Net income for 2010 was $736,692 compared to a net loss of $440,377 in 2009. Operating income was $970,567 in 2010 compared to $15,477 in 2009. The non-GAAP Company-defined adjusted EBITDA, as described in the Company's Management Discussion and Analysis public filings, was $1,222,000 in FY 2010, compared to $293,000 in FY 2009. Earnings per share for 2011 were $0.05 compared to a loss of $0.03 for 2010.
"The Company has successfully managed its way out of the recession and is now poised for significant revenue growth. The Company's Mobile Web technology will become the foundation for all products and services in 2011. At the Event Marketing Summit, May 16-18 in Chicago the company will launch "In-Touch Apps for Events" - the world's first hardware independent, mobile-web solution, for the marketing departments of Fortune 1,000 firms and their Agencies of Record", said Michael Gaffney, Chief Executive Officer.
"The new IMS division, which sells In-Touch Mobile-Web solutions into Government, is close to achieving its 2011 bookings targets, and expected revenues are $1,000,000 this year. We are actively searching for additional sales opportunities from American and Canadian governments and believe that our technology, already in use by large private sector enterprises, has significant value for governments. A pilot data-capture project just completed with the Canadian Military, looks very promising, in terms of growth, and will provide an excellent reference customer. In addition to significant growth in Canadian Government revenues, our revenues from the US military (Army, Air Force and Navy) will increase in 2011 compared to 2010", said Gaffney.
The company continues to forecast 2011 revenue growth of at least 25% compared to 2010. Most of the growth will occur in Q2, Q3 and Q4. The company expects 2011 bookings to exceed 2010 revenue by the end of April 2011. Q1 2011 revenues are expected to be 5-8% higher than Q1 2010. The Company has increased its spending in product development and marketing, given its revenue growth expectations, and breakeven is approximately $1.4M per quarter.
Consolidated Statements 2010 2009
of Operations
Revenue $ 5,893,125 $ 5,479,081
Cost of services and 2,125,290 2,200,533
goods sold
Gross profit 3,767,835 3,278,548
Total operating 2,798,530 3,263,071
expenses
Earnings before 969,305 15,477
undernoted items
Interest expense on (24,048) (23,996)
short term debt
Interest expense on (70,077) (109,300)
long term debt
\Interest on capital (842) (21,465)
leases
Amortization of - (10,682)
financing costs
Amortization of - (9,596)
intangible asset
Change in fair value of (97,109) (33,956)
derivative
Gain (loss) on foreign (45,235) (85,422)
exchange
Gain on disposal of 4,698 12,745
property and equipment
Impairment of franchise - (31,193)
Impairment of - (142,989)
intangible assets and
goodwill
Net earnings (loss) $ 736,692 $ (440,377)
NEI starting to look better-don't let this one go up w/o you having a position...strong future here...at 2.05 up .04 on 190,000 v MC
INX.v remains best buy for value and rapid growth top and bottom lines of any mobile play out here-at .345 it's one helluva buy...MC
MCZ starting to come back after some well deserved profit taking-stck is at 2.16 up .11 on heavy vol of 1m-this is a favorite mobile play of mine...MC
CEMI .56...chart says go...so does year end-maybe today-
CEMI--.$.55ferrari chart formation x 2-unusual to have 2 so tight one following the other--
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=cemi&insttype=&freq=1&show=&time=8
Then a long look back at last year and ahead to this FY-also I listened to the conf call and suggest it is worth the time-
Chembio Reports Record Annual & Quarterly Results
Conference Call Scheduled for Thursday, March 3, 2011, at 10:00 a.m. Eastern Time
marketwire
Press Release Source: Chembio Diagnostics, Inc. On Thursday March 3, 2011, 8:00 am EST
MEDFORD, NY--(Marketwire - 03/03/11) - Chembio Diagnostics, Inc. (Pinksheets:CEMI - News) (Pinksheets:CEMI - News), which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported record revenues and earnings for the year ended December 31, 2010. Total revenues were $16.7 million for the year ended December 31, 2010, which compares to total revenues of $13.8 million for the year ended December 31, 2009, a 20.8% increase. The Company recorded net income of approximately $2.51 million, or $0.04 per share, for the year ended December 31, 2010, compared to net income of approximately $309,000, or less than $0.01 per share, for the year ended December 31, 2009. Total revenues were $5.67 million for the three months ended December 31, 2010, which compares to total revenues of $3.55 million for the three months ended December 31, 2009, a 60% increase. The Company recorded net income of approximately $1.88 million, or $0.03 per share, for the three months ended December 31, 2010, compared to a net income of approximately $217,000, or less than $0.01 per share, for the three months ended December 31, 2009.
The Company realized a record amount of revenues related to research & development milestones and grants, which increased 106% to $2.76 million in the year ended December 31, 2010 from $1.34 million in the year ended December 31 2009. Also contributing to the record revenues was an 83% increase in sales of the Company's rapid HIV tests to customers in Africa where its products are used in national testing programs principally funded by the U.S. President's Emergency Plan for AIDS Relief ("PEPFAR") and/or the Global Fund to Fight AIDS, Tuberculosis & Malaria. The Company's 2010 DPP® product sales were $.63 million, level with 2009. However all of the 2009 DPP® product sales were for evaluations and regulatory submissions undertaken by FIOCRUZ, the Company's OEM customer in Brazil; most of the 2010 sales were the initial sales of product that would be used in a new national testing protocol being considered in Brazil.
The operating results in 2010 include $5.28 million of revenues from the sale of rapid HIV tests to Alere, Inc. ("Alere" formerly Inverness Medical Innovations, Inc.), the Company's exclusive U.S. marketing partner for its two FDA approved rapid HIV tests. This represents an increase of $40,000, or less than 1%, compared to $5.24 million for the year ended December 31, 2009. Sales to Alere in the fourth quarter of 2010 were $1.74 million, a decrease of $93,000 or 5% as compared to the fourth quarter in 2009. During 2010 we believe Alere increased its sales of our products by at least 25%, however due to inventory level changes at Alere, this is not reflected in our results. During 2010 we also completed paying the $1.01 million liability to Alere that we incurred in 2008, which will enhance our future cash flows.
The 2010 operating results include $1.47 million in Qualified Therapeutic Discovery Project grants ("QTDP") under Section 48D of the Internal Revenue Code, as enacted under the Patient Protection and Affordable Care Act of 2010. This amount was reflected as a reduction of research and development expenses (R&D).
The operating results also included approximately $275,000 of expenses incurred in connection with two specific potential strategic opportunities, including approximately $100,000 for legal fees, including patent research and due diligence, $100,000 for outside directors' Special Committee fees, $37,500 for a valuation consultant deposit, $25,000 for investment consulting fees and $12,500 in various other expenses. One of these potential opportunities, which was unsolicited, involved due diligence, travel and negotiation, and preparation of a written agreement which was not finalized, and the other involved travel and extensive negotiations and due diligence. Both opportunities involved numerous meetings, conferences and discussions by and with management, Chembio's outside directors and counsel, both for internal strategy sessions and with the proposed strategic partner. Neither of the potential opportunities ultimately resulted in any material agreement. The Company's senior management and board believes strongly in the value that has been created and the opportunities there are for further increasing shareholder value, particularly once it begins to commercialize the products in its development and clinical pipeline. Chembio continues to consider strategic opportunities that it believes are attractive. Finally, we expended approximately $650,000 of clinical trial expenses in 2010 related to our oral fluid HIV test PMA, including $253,000 in the fourth quarter.
The $275,000 in strategic investigation costs in SG&A expenses, $1.467 million QTDP benefit (expense reduction), and the $650,000 clinical trial expense each had a material impact on our 2010 net income.
Commenting on the results, Chembio's President, Lawrence A. Siebert, stated, "We are very pleased with our 2010 results, which included strong growth in our base business of lateral flow HIV tests, and record revenue from research and development contracts and grants, all of which enabled us to increase our investment in our new and growing DPP® product pipeline. I believe we are very well positioned to deliver continued growth in 2011 and beyond, as the growth from our base business is accelerated from the commercialization of our new DPP® rapid, point-of-care products. We believe that our strategy of developing a core public health brand, initially with our DPP® HIV Oral Fluid HIV test and our DPP® Syphilis Screen & Confirm test, and of complementing this business with OEM opportunities in all other market segments, is sound and will continue."
Financial Highlights for 2010
-- Product sales for the year ended December 31, 2010 increased 9% to a
record $13.52 million from $12.37 million in 2009, which was the
Company's previous record for revenues. Net product sales to Alere for
the year remained steady, as compared with the year of 2009.
-- Product sales also included the shipment of HIV rapid tests and
components to customers in Africa ($6.13MM), South America ($1.05MM),
and Asia, Europe, and the Middle East ($.36MM).
-- Also included in our 2010 product sales was $628,100 of DPP® product
sales, an increase of 1%, or $8,600, as compared to $619,500 in 2009.
These sales were for two of the four DPP® products we contracted for
In 2008 with our Brazilian customer FIOCRUZ. Approximately $84,000 of
these sales reflect products provided FIOCRUZ' to submit product for
evaluation, laboratory and field studies, and regulatory approval. The
balance was for the DPP® HIV 1/2 Screen test. Delays have occurred in
FIOCRUZ obtaining certain other regulatory approvals, although we
believe that these regulatory approvals will be achieved during the
first and/or second quarters of 2011.
-- The increased product and R&D, milestone and grant revenues combined
to produce gross margin dollars that were $2.24 million, or 38%,
greater ($8.10 million vs. $5.86 million) in 2010 than the gross
margin dollars in 2009.
-- Research and development expenses, excluding the effect of the QTDP
grants, increased by $1.17 million, or 41%, to $4.05 million compared
to $2.88 million in the 2009 period. The QTDP grant reduced research
and development expenses in 2010 to $2.59 million. The Company has
nevertheless over the same period increased its research & development
expenses, as more products based on the Company's patented DPP®
technology were validated for manufacture and entered the clinical
evaluation and regulatory approval process.
-- The operating results also include approximately $654,000 of clinical
trials expenses ongoing in support of an FDA Pre-Marketing Approval
("PMA") related to its DPP® HIV 1/2 screening test for use with oral
fluid or blood samples.
-- Selling General & Administrative Expenses increased by $281,000, or
10.6%, in the year of 2010 as compared to the year of 2009. This was
primarily due to the recording of $94,000 in Brazilian tax withholdings
on the milestone payments and an increase in investor relations.
-- Operating income was approximately $2.57 million in 2010 as compared to
operating income in 2009 of $.32 million, an increase of $2.25 million.
In addition, net income was approximately $2.51 million in 2010 as
compared to net income in 2009 of $309,000, an increase of $2.20
million.
-- The December 31, 2010 cash balance was $1.07 million more than as of
December 31, 2009. This was primarily due to $1.02 million in cash
provided from operations. Also contributing to the cash increase was
a $250,000 term loan from HSBC. Partially offsetting these cash inflows
was our investment in fixed assets.
Financial Highlights for the Quarter ended December 31, 2010
-- Product sales for the quarter ended December 31, 2010 (fourth quarter)
increased 65.6% to $5.18 million from $3.13 million in the same period
of 2009.
-- R&D revenues for the fourth quarter increased $70,000 to $456,000 from
$386,000 in the same period of 2009
-- The increased product and R&D revenues in the fourth quarter of 2010,
together with the effect of the QTDP grants, combined to produce gross
margin dollars that were $.86 million, or 53%, greater ($2.51 million
vs. $1.63 million) than the gross margin dollars in the comparable
period in 2009.
-- Research and development expenses, excluding the effect of the QTDP
grants, increased by $.48 million or 63% to $1.23 million compared to
$.76 million in the 2009 period. The QTDP grants reduced research and
development expenses to $(.24) million in the 2010 period.
-- Selling General & Administrative Expenses increased by $140,000 or 21%
in the fourth quarter of 2010 as compared to the fourth quarter of
2009. This was primarily due to an increase in commissions for the
increased sales made to Brazil of our DPP® products.
-- Operating profit was approximately $1.93 million, in the fourth quarter
of 2010 as compared to operating income in the fourth quarter of 2009
of $218,000, an increase of $1.71 million. In addition, net income was
approximately $1.88 million in the fourth quarter of 2010 as compared
to net income in the fourth quarter of 2009 of $217,000, an increase of
$1.66 million. The QTDP grants had a significant impact upon both
operating profit and net income for the fourth quarter of 2010.
Information Concerning the Market for our Common Stock
On February 24, 2011, and since that date, our stock has not been quoted on the OTC Bulletin Board, and is now being quoted on the OTCQB, which is the second of the three tiers of the OTC Market Group. The situation is in a state of flux and we are trying to determine what market we believe is best for our stock, considering the relative costs, liquidity, market strategy, etc. The other markets that we will consider are (1) the higher tier of the OTC Market Group called OTC-QX; (2) the NYSE-AMEX, and; (3) NASDAQ. Our stock is no longer trading on the OTC Bulletin Board because the market maker that had filed originally to quote our stock on the OTC Bulletin Board is no longer providing quotes on the OTC Bulletin Board. It is our understanding that a large number of other market makers also have ceased to provide quotes on the OTC Bulletin Board and that 300 to 500 other companies have ceased being quoted on the OTC Bulletin Board during the past few months for the same reason.
This change has nothing to do with Chembio or the quality of our company. It is solely related to the desire of the market makers to save costs related to providing quotes on the OTC Bulletin Board.
Certain third-party stock data providers such as Yahoo Finance are still in the process of updating their platforms to correctly display the trading activity of companies that have transitioned from OTCBB to OTCQB. For price and volume information regarding Chembio on the OTCQB marketplace please visit: http://www.otcmarkets.com/stock/CEMI/quote
Summary of R&D, Clinical and Commercialization Programs
-- DPP® HIV Oral Fluid Screening Assay - During 2010 we made significant
progress toward commercializing this product globally, as follows.
-- FDA PMA Application Status - We commenced clinical trials in the
United States in support of a planned Pre-Marketing Approval (PMA)
application to the FDA. We have enrolled about half of the 3,000
patients in the clinical protocol and we are on a schedule for
completing this clinical trial this summer. We recently submitted a
request to file a modular PMA to the FDA which allows us to submit
our preclinical data and manufacturing information for review while
still collecting, compiling and analyzing clinical data. The first,
second and third modules are being planned for submission to FDA in
the first, second and third quarters, respectively.
-- International Market - In March we obtained approval of this product
from the United States PEPFAR program, and reported the results of
studies done in Mozambique and Nigeria supporting this approval
which demonstrating excellent performance of this product. We are
submitting this product for inclusion in the WHO procurement list as
well.
-- DPP® Syphilis Screen & Confirm Test -
-- US FDA Clearance - We are completing the internal processes necessary
to commence clinical studies for the products in the United States.
Clinical studies are being scheduled for 2nd Quarter of this year to
support the FDA pre-market clearance (510k). A study we conducted in
collaboration with the CDC that was published in December in the
Journal of Clinical Microbiology, as well as studies reported by CDC
confirm the value of our multiplex DPP® Syphilis Screen & Confirm
test.
-- China Evaluation - Through our ongoing collaboration with the CDC for
this product, we were invited by the WHO Collaborating Center in
China to conduct a training session there in January for a multi-site
evaluation of this product which is starting now and that is
scheduled to be completed during the second quarter. Our DPP®
patent was just issued in China, where syphilis is on the rise, and
we have begun to consider various opportunities for distribution and
manufacturing of our products there, including but not limited to
this product.
-- CE Mark - When we are ready to begin the clinical studies for this
product we will alos be able to submit this product for
self-certification of a CE Mark, which submission we anticipate
filing in the 2nd quarter 2011.
-- FIOCRUZ Programs - We have five active projects with FIOCRUZ, four
relating to agreements signed in 2008 and one (Syphilis) signed in
2010.
-- Approval of DPP® HIV Screening and Confirmatory Assays - During
2010 ANVISA granted FIOCRUZ approval to market our DPP® HIV 1/2
Screening and Confirmatory Tests. We believe the Ministry of
Health in Brazil is seeking to have these products used in a new
serial testing algorithm to be deployed nationally, and that an
evaluation concerning this new algorithm is ongoing.
-- DPP® Canine Leishmaniasis - In January 2011 FIOCRUZ was requested
by MAPA for the second time to provide additional information.
This will further delay the approval process and based upon recent
experience it is difficult to predict timing. Nevertheless, based
on our discussions with FIOCRUZ, we believe there remains strong
support for this product within FIOCRUZ and that they are
continuing their efforts in prosecuting the approval of this product
by MAPA.
-- DPP® Leptospirosis - Chembio sent three production lots of this
product to FIOCRUZ and FIOCRUZ is completing the preparation of a
technical file in order to submit to ANVISA for approval. FIOCRUZ
estimates ANVISA approval will be granted during the second quarter
of 2011.
-- DPP® Syphilis Treponemal - Chembio sent three production lots of to
FIOCRUZ and FIOCRUZ is completing the preparation of a technical
file in order to submit to ANVISA for approval. FIOCRUZ estimates
ANVISA approval will be granted during the second quarter of 2011.
We also had significant progress on the following projects in 2010
-- Bio-Rad Laboratories OEM Multiplex DPP® Agreement - In June 2010
Bio-Rad confirmed that the product development activity had been
completed in accordance with the agreed-upon specifications,
resulting in a license fee being earned. At that time Bio-Rad also
exercised its option to have Chembio transfer the manufacturing of
this product to Bio-Rad, which process was also satisfactorily
completed, in October 2010, resulting in additional agreed-upon
fees being earned. We believe that Bio-Rad will begin to market
this product in Europe beginning in 2012, and in the United States
in 2013, although there can be no assurance of this. During 2010,
Chembio earned approximately $128,000 for product development work
rendered to Bio-Rad under this agreement, plus an additional $615,000
in license and other fees related to the manufacturing transfer.
-- Battelle/CDC DPP® Multiplex Influenza Immunity Test - In
December 2009 Chembio entered into a milestone-based development
agreement for the development and initial supply of a multiplex,
rapid point-of-care ("POC") influenza immunity test. During 2010
development work with respect to the contract development
specification was substantially completed. Our contract partners are
assessing the prototype product and determining potential additional
funded development activity. During 2010, Chembio earned approximately
$804,000 in milestones for product development work rendered under
this agreement.
-- DPP® Influenza - We have developed a prototype multiplex test for
FLU A/B Antigen Detection and plan to complete R&D development for
this test in March 2011 and to complete validation by the end of the
second quarter of 2011. We will submit our pre-IDE to 510K in July 2011
based on our current plan. This will help us to conduct clinical trials
during late 2011 and/or early 2012.
-- DPP® Leptospirosis Phase II Grant - In 2009 we were awarded a three
year, $1.9 million Small Business Innovative Research (SBIR) Phase II
grant from the United States National Institutes of Health (NIH) to
fully develop, validate, and commercialize a rapid diagnostic test for
Leptospirosis for general use worldwide, and our work is progressing
on schedule. To date, we have identified several novel leptospiral
proteins cloned from a variety of strains that are prevalent in
different countries. These antigens will supplement the current test
prototype and thus enhance the potential for its use worldwide as a
universal point-of-care test for leptospirosis.
-- DPP® Tuberculosis Phase II Grant - In February 2011 we were awarded
an SBIR Phase II grant from the NIH to continue development of a simple,
rapid, accurate, and cost-effective serological test for active
tuberculosis that can be utilized in resource-limited settings.
Chembio developed a prototype of this test in the Phase I work in
collaboration with the Infectious Disease Research Institute ("IDRI"),
a Seattle-based biotechnology research organization dedicated to
technologies that address diseases in the developing world; this
collaboration will continue in this second phase of the research and
development grant as well. The grant is effective March 1, 2011. The
prototype test developed during the Phase I work uses the Dual Path
Platform (DPP®) technology together with selected antigens from a
large panel of novel recombinant antigens identified at IDRI. The
Phase I studies demonstrated the feasibility of developing a rapid
and accurate test for tuberculosis with required diagnostic
performance characteristics (sensitivity > 80%, specificity > 95%).
In Phase II, the proposed rapid (15 minutes) point-of-care DPP® test
for tuberculosis will be fully developed, optimized, and evaluated
in multi-center clinical trials in several countries, followed by
validation of production protocols, preparation for regulatory
approval and commercialization
-- DPP® Hepatitis C - In 2010 we received data from a study sponsored by
the CDC that assessed the performance of our HCV product. The data,
which we believe will be published soon, confirmed that we had
achieved good performance with this HCV antibody detection test
prototype. We have recently been invited to participate in some
additional CDC studies this year with this and certain other
related prototype products that we have in development in this
area. We have also determined however that the market opportunity
for a point of care HCV antibody only (i.e., without antigen detection)
test is very limited, and so in addition to improving our antibody
detection test, we are also working on including antigen detection as
well as in a new DPP® format that we have in development, which format
incorporates some of our platform enhancements (see below). We believe
this could result in a more commercially viable market opportunity for
this market.
Other Activities & Developments
-- Platform Enhancements - During 2010 and increasingly during 2011
we are improving and enhancing the capabilities of our DPP®
technology. For example, we are further simplifying the procedure
to run certain kinds of tests developed with DPP® and we are also
making antibody and antigen detection available in a single test
device without certain limitations that exist when this is attempted
with lateral flow technology.
-- Operations - We have also fully integrated the new automated assembly
system into our manufacturing operation, which will make all of our
production, both lateral flow and DPP®, more cost effective.
-- Patents Issued & Pending - The Company has obtained patent coverage on
the DPP® product line, including three U.S. patents, and patents in
China, Malaysia, Eurasia, Mexico, Singapore, and the U.K. Additional
patents applications on the DPP® product line are pending in the U.S.,
as well as in many foreign countries such as Australia, Brazil, Canada,
the European Union, India, Indonesia, Israel, Japan, Korea, and
South Africa. Patents have also been filed on extensions to the DPP®
product line concept.
There can be no assurance that any of these projects will continue, meet regulatory or other technical requirements and specifications, and/or that if continued, will result in completed products, or that such products, if successfully completed, will be successfully commercialized.
Conference Call
Chembio has scheduled a conference call and webcast for 10:00 a.m. Eastern time on Thursday, March 3, 2011. To participate on the conference call, please dial (877) 407-0778 from the U.S. or (201) 689-8565 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until March 10, 2011 at 11:59 p.m. Eastern Time by dialing (877) 660-6853 from the U.S. or (201) 612-7415 from outside the U.S. and entering reservation account number 286 and conference ID #: 36779. The conference call may also be accessed via the internet at http://www.investorcalendar.com/IC/CEPage.asp?ID=163520. An archive of the webcast will be available for 90 days on the Company's website at www.chembio.com.
Investor Presentation
The Company has prepared and filed a new investor presentation. It can be accessed through the following link: http://phx.corporate-ir.net/phoenix.zhtml?c=121584&p=irol-IRhome.
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $7 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Inverness Medical Innovations, Inc. Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP®. Headquartered in Medford, NY, with approximately 100 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485.
OPL.v big jump today...maybe all the valuation scenarios are now about figured out...kinda hard to see how you miss w/an independent valuation of about $1B-cautioned of course by fact that much has to still be proved out with POET--and sh ct of 85m with company still going full bore into solar...change in valuation thus far for OPL is from approx .35 prior to announcement to 1.12 close today. Diff in sh price/value is .77x.85=$65m-seems a bit low to me...should be maybe more like 2.50-3.00. MC
INX.v...$.35-this is a strong play in the MOBILE wave that is going to dwarf the size of the internet. I have talked with CEO often over past 6mo and am convinced of their game plan's success...going to be a helluva year this year and in my opinion a stronger year next year as well...growth velocity picking up as is amt falling to bottom line-gpg
IN-TOUCH SURVEY SYSTEMS LTD. ANNOUNCES ANNUAL FINANCIAL RESULTS WITH SIGIFICANTLY IMPROVED PROFITS AND CASH FLOW
cnwgroup
Press Release Source: In-Touch Insight Systems Inc. On Tuesday April 12, 2011, 4:17 pm EDT
OTTAWA, April 12 /CNW/ - In-Touch Survey Systems Ltd. ("In-Touch" TSX-Venture: INX) announces that revenue increased 8% to $5,893,125 in FY 2010 compared to $5,479,081 in FY 2009. Net income for 2010 was $736,692 compared to a net loss of $440,377 in 2009. Operating income was $970,567 in 2010 compared to $15,477 in 2009. The non-GAAP Company-defined adjusted EBITDA, as described in the Company's Management Discussion and Analysis public filings, was $1,222,000 in FY 2010, compared to $293,000 in FY 2009. Earnings per share for 2011 were $0.05 compared to a loss of $0.03 for 2010.
"The Company has successfully managed its way out of the recession and is now poised for significant revenue growth. The Company's Mobile Web technology will become the foundation for all products and services in 2011. At the Event Marketing Summit, May 16-18 in Chicago the company will launch "In-Touch Apps for Events" - the world's first hardware independent, mobile-web solution, for the marketing departments of Fortune 1,000 firms and their Agencies of Record", said Michael Gaffney, Chief Executive Officer.
"The new IMS division, which sells In-Touch Mobile-Web solutions into Government, is close to achieving its 2011 bookings targets, and expected revenues are $1,000,000 this year. We are actively searching for additional sales opportunities from American and Canadian governments and believe that our technology, already in use by large private sector enterprises, has significant value for governments. A pilot data-capture project just completed with the Canadian Military, looks very promising, in terms of growth, and will provide an excellent reference customer. In addition to significant growth in Canadian Government revenues, our revenues from the US military (Army, Air Force and Navy) will increase in 2011 compared to 2010", said Gaffney.
The company continues to forecast 2011 revenue growth of at least 25% compared to 2010. Most of the growth will occur in Q2, Q3 and Q4. The company expects 2011 bookings to exceed 2010 revenue by the end of April 2011. Q1 2011 revenues are expected to be 5-8% higher than Q1 2010. The Company has increased its spending in product development and marketing, given its revenue growth expectations, and breakeven is approximately $1.4M per quarter.
Consolidated Statements of Operations 2010 2009
Revenue $ 5,893,125 $ 5,479,081
Cost of services and goods sold 2,125,290 2,200,533
Gross profit 3,767,835 3,278,548
Total operating expenses 2,798,530 3,263,071
Earnings before undernoted items 969,305 15,477
Interest expense on short term debt (24,048) (23,996)
Interest expense on long term debt (70,077) (109,300)
Interest on capital leases (842) (21,465)
Amortization of financing costs - (10,682)
Amortization of intangible asset - (9,596)
Change in fair value of derivative (97,109) (33,956)
Gain (loss) on foreign exchange (45,235) (85,422)
Gain on disposal of property and equipment 4,698 12,745
Impairment of franchise - (31,193)
Impairment of intangible assets and goodwill - (142,989)
Net earnings (loss) $ 736,692 $ (440,377)
INT.v announced acq...looks damn interesting...stock backing off...investors trying to figure out..cost is 6m shares AT .74. THERE WAS ANOTHER PR YEST WHICH WAS EVEN MORE FASCINATING. TAKE A LOOK WHO IS BEHIND int.V IN ADDITION TO GENE SIMMONS AND ALSO TAKE A LOOK AT GUYS BEHIND NEW ACQ. LOOK AT VELOCITY OF RAMP UP IN VIEWS FOR INT.V'S SUBS.
Now--stock reached HOD of approx 1.22cad (that matters now as Looney is 1.04 over US buck)around 3.30 or so and then the first PR hit ref the acq-investors had to ponder and stock backed off and closed at 1.05. After reading 2nd PR from yest I am more convinced than ever that we could have a dynamic play here w/no top. I had cleared out all my INT 5 min prior to PR-dumb luck-and dtarted new position around 1.10us. WATCH LEVEL 2 BEGINNING AROUND 9.15A FOR CLUE AS TO DIRECTION AND STRENGTH FOR INT.V OPEN THIS AM.
MC
CEMI....$.48....this is a REAL interesting situation...just on the one year chart look what you have--7 months of very tight range bound trading at .25 then sharp move up to .40-.45 and range bound trading for last 5 months until just last week. This looks good any way you cut it.
I picked up the chart formation over w/e using a screen then went to catch up with the company as I have known them a long time. Their year end just came out, was a record, and man o man was there a lot under the hood...which I will list below chart. First run thru I thought they were just taking up spce but there guys have a lot on the ball---see for yourself below chart--->>
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=cemi&insttype=&freq=1&show=True&time=8
Chembio Reports Record Annual & Quarterly Results
Conference Call Scheduled for Thursday, March 3, 2011, at 10:00 a.m. Eastern Time
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o CHEMBIO DIAGNOSTICS
Related Quotes
Symbol Price Change
CEMI.PK 0.4750 -0.0050
Chart for CHEMBIO DIAGNOSTICS
{"s" : "cemi.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Chembio Diagnostics, Inc. On Thursday March 3, 2011, 8:00 am EST
MEDFORD, NY--(Marketwire - 03/03/11) - Chembio Diagnostics, Inc. (Pinksheets:CEMI - News) (Pinksheets:CEMI - News), which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported record revenues and earnings for the year ended December 31, 2010. Total revenues were $16.7 million for the year ended December 31, 2010, which compares to total revenues of $13.8 million for the year ended December 31, 2009, a 20.8% increase. The Company recorded net income of approximately $2.51 million, or $0.04 per share, for the year ended December 31, 2010, compared to net income of approximately $309,000, or less than $0.01 per share, for the year ended December 31, 2009. Total revenues were $5.67 million for the three months ended December 31, 2010, which compares to total revenues of $3.55 million for the three months ended December 31, 2009, a 60% increase. The Company recorded net income of approximately $1.88 million, or $0.03 per share, for the three months ended December 31, 2010, compared to a net income of approximately $217,000, or less than $0.01 per share, for the three months ended December 31, 2009.
The Company realized a record amount of revenues related to research & development milestones and grants, which increased 106% to $2.76 million in the year ended December 31, 2010 from $1.34 million in the year ended December 31 2009. Also contributing to the record revenues was an 83% increase in sales of the Company's rapid HIV tests to customers in Africa where its products are used in national testing programs principally funded by the U.S. President's Emergency Plan for AIDS Relief ("PEPFAR") and/or the Global Fund to Fight AIDS, Tuberculosis & Malaria. The Company's 2010 DPP® product sales were $.63 million, level with 2009. However all of the 2009 DPP® product sales were for evaluations and regulatory submissions undertaken by FIOCRUZ, the Company's OEM customer in Brazil; most of the 2010 sales were the initial sales of product that would be used in a new national testing protocol being considered in Brazil.
The operating results in 2010 include $5.28 million of revenues from the sale of rapid HIV tests to Alere, Inc. ("Alere" formerly Inverness Medical Innovations, Inc.), the Company's exclusive U.S. marketing partner for its two FDA approved rapid HIV tests. This represents an increase of $40,000, or less than 1%, compared to $5.24 million for the year ended December 31, 2009. Sales to Alere in the fourth quarter of 2010 were $1.74 million, a decrease of $93,000 or 5% as compared to the fourth quarter in 2009. During 2010 we believe Alere increased its sales of our products by at least 25%, however due to inventory level changes at Alere, this is not reflected in our results. During 2010 we also completed paying the $1.01 million liability to Alere that we incurred in 2008, which will enhance our future cash flows.
The 2010 operating results include $1.47 million in Qualified Therapeutic Discovery Project grants ("QTDP") under Section 48D of the Internal Revenue Code, as enacted under the Patient Protection and Affordable Care Act of 2010. This amount was reflected as a reduction of research and development expenses (R&D).
The operating results also included approximately $275,000 of expenses incurred in connection with two specific potential strategic opportunities, including approximately $100,000 for legal fees, including patent research and due diligence, $100,000 for outside directors' Special Committee fees, $37,500 for a valuation consultant deposit, $25,000 for investment consulting fees and $12,500 in various other expenses. One of these potential opportunities, which was unsolicited, involved due diligence, travel and negotiation, and preparation of a written agreement which was not finalized, and the other involved travel and extensive negotiations and due diligence. Both opportunities involved numerous meetings, conferences and discussions by and with management, Chembio's outside directors and counsel, both for internal strategy sessions and with the proposed strategic partner. Neither of the potential opportunities ultimately resulted in any material agreement. The Company's senior management and board believes strongly in the value that has been created and the opportunities there are for further increasing shareholder value, particularly once it begins to commercialize the products in its development and clinical pipeline. Chembio continues to consider strategic opportunities that it believes are attractive. Finally, we expended approximately $650,000 of clinical trial expenses in 2010 related to our oral fluid HIV test PMA, including $253,000 in the fourth quarter.
The $275,000 in strategic investigation costs in SG&A expenses, $1.467 million QTDP benefit (expense reduction), and the $650,000 clinical trial expense each had a material impact on our 2010 net income.
Commenting on the results, Chembio's President, Lawrence A. Siebert, stated, "We are very pleased with our 2010 results, which included strong growth in our base business of lateral flow HIV tests, and record revenue from research and development contracts and grants, all of which enabled us to increase our investment in our new and growing DPP® product pipeline. I believe we are very well positioned to deliver continued growth in 2011 and beyond, as the growth from our base business is accelerated from the commercialization of our new DPP® rapid, point-of-care products. We believe that our strategy of developing a core public health brand, initially with our DPP® HIV Oral Fluid HIV test and our DPP® Syphilis Screen & Confirm test, and of complementing this business with OEM opportunities in all other market segments, is sound and will continue."
Financial Highlights for 2010
-- Product sales for the year ended December 31, 2010 increased 9% to a
record $13.52 million from $12.37 million in 2009, which was the
Company's previous record for revenues. Net product sales to Alere for
the year remained steady, as compared with the year of 2009.
-- Product sales also included the shipment of HIV rapid tests and
components to customers in Africa ($6.13MM), South America ($1.05MM),
and Asia, Europe, and the Middle East ($.36MM).
-- Also included in our 2010 product sales was $628,100 of DPP® product
sales, an increase of 1%, or $8,600, as compared to $619,500 in 2009.
These sales were for two of the four DPP® products we contracted for
In 2008 with our Brazilian customer FIOCRUZ. Approximately $84,000 of
these sales reflect products provided FIOCRUZ' to submit product for
evaluation, laboratory and field studies, and regulatory approval. The
balance was for the DPP® HIV 1/2 Screen test. Delays have occurred in
FIOCRUZ obtaining certain other regulatory approvals, although we
believe that these regulatory approvals will be achieved during the
first and/or second quarters of 2011.
-- The increased product and R&D, milestone and grant revenues combined
to produce gross margin dollars that were $2.24 million, or 38%,
greater ($8.10 million vs. $5.86 million) in 2010 than the gross
margin dollars in 2009.
-- Research and development expenses, excluding the effect of the QTDP
grants, increased by $1.17 million, or 41%, to $4.05 million compared
to $2.88 million in the 2009 period. The QTDP grant reduced research
and development expenses in 2010 to $2.59 million. The Company has
nevertheless over the same period increased its research & development
expenses, as more products based on the Company's patented DPP®
technology were validated for manufacture and entered the clinical
evaluation and regulatory approval process.
-- The operating results also include approximately $654,000 of clinical
trials expenses ongoing in support of an FDA Pre-Marketing Approval
("PMA") related to its DPP® HIV 1/2 screening test for use with oral
fluid or blood samples.
-- Selling General & Administrative Expenses increased by $281,000, or
10.6%, in the year of 2010 as compared to the year of 2009. This was
primarily due to the recording of $94,000 in Brazilian tax withholdings
on the milestone payments and an increase in investor relations.
-- Operating income was approximately $2.57 million in 2010 as compared to
operating income in 2009 of $.32 million, an increase of $2.25 million.
In addition, net income was approximately $2.51 million in 2010 as
compared to net income in 2009 of $309,000, an increase of $2.20
million.
-- The December 31, 2010 cash balance was $1.07 million more than as of
December 31, 2009. This was primarily due to $1.02 million in cash
provided from operations. Also contributing to the cash increase was
a $250,000 term loan from HSBC. Partially offsetting these cash inflows
was our investment in fixed assets.
Financial Highlights for the Quarter ended December 31, 2010
-- Product sales for the quarter ended December 31, 2010 (fourth quarter)
increased 65.6% to $5.18 million from $3.13 million in the same period
of 2009.
-- R&D revenues for the fourth quarter increased $70,000 to $456,000 from
$386,000 in the same period of 2009
-- The increased product and R&D revenues in the fourth quarter of 2010,
together with the effect of the QTDP grants, combined to produce gross
margin dollars that were $.86 million, or 53%, greater ($2.51 million
vs. $1.63 million) than the gross margin dollars in the comparable
period in 2009.
-- Research and development expenses, excluding the effect of the QTDP
grants, increased by $.48 million or 63% to $1.23 million compared to
$.76 million in the 2009 period. The QTDP grants reduced research and
development expenses to $(.24) million in the 2010 period.
-- Selling General & Administrative Expenses increased by $140,000 or 21%
in the fourth quarter of 2010 as compared to the fourth quarter of
2009. This was primarily due to an increase in commissions for the
increased sales made to Brazil of our DPP® products.
-- Operating profit was approximately $1.93 million, in the fourth quarter
of 2010 as compared to operating income in the fourth quarter of 2009
of $218,000, an increase of $1.71 million. In addition, net income was
approximately $1.88 million in the fourth quarter of 2010 as compared
to net income in the fourth quarter of 2009 of $217,000, an increase of
$1.66 million. The QTDP grants had a significant impact upon both
operating profit and net income for the fourth quarter of 2010.
Information Concerning the Market for our Common Stock
On February 24, 2011, and since that date, our stock has not been quoted on the OTC Bulletin Board, and is now being quoted on the OTCQB, which is the second of the three tiers of the OTC Market Group. The situation is in a state of flux and we are trying to determine what market we believe is best for our stock, considering the relative costs, liquidity, market strategy, etc. The other markets that we will consider are (1) the higher tier of the OTC Market Group called OTC-QX; (2) the NYSE-AMEX, and; (3) NASDAQ. Our stock is no longer trading on the OTC Bulletin Board because the market maker that had filed originally to quote our stock on the OTC Bulletin Board is no longer providing quotes on the OTC Bulletin Board. It is our understanding that a large number of other market makers also have ceased to provide quotes on the OTC Bulletin Board and that 300 to 500 other companies have ceased being quoted on the OTC Bulletin Board during the past few months for the same reason.
This change has nothing to do with Chembio or the quality of our company. It is solely related to the desire of the market makers to save costs related to providing quotes on the OTC Bulletin Board.
Certain third-party stock data providers such as Yahoo Finance are still in the process of updating their platforms to correctly display the trading activity of companies that have transitioned from OTCBB to OTCQB. For price and volume information regarding Chembio on the OTCQB marketplace please visit: http://www.otcmarkets.com/stock/CEMI/quote
Summary of R&D, Clinical and Commercialization Programs
-- DPP® HIV Oral Fluid Screening Assay - During 2010 we made significant
progress toward commercializing this product globally, as follows.
-- FDA PMA Application Status - We commenced clinical trials in the
United States in support of a planned Pre-Marketing Approval (PMA)
application to the FDA. We have enrolled about half of the 3,000
patients in the clinical protocol and we are on a schedule for
completing this clinical trial this summer. We recently submitted a
request to file a modular PMA to the FDA which allows us to submit
our preclinical data and manufacturing information for review while
still collecting, compiling and analyzing clinical data. The first,
second and third modules are being planned for submission to FDA in
the first, second and third quarters, respectively.
-- International Market - In March we obtained approval of this product
from the United States PEPFAR program, and reported the results of
studies done in Mozambique and Nigeria supporting this approval
which demonstrating excellent performance of this product. We are
submitting this product for inclusion in the WHO procurement list as
well.
-- DPP® Syphilis Screen & Confirm Test -
-- US FDA Clearance - We are completing the internal processes necessary
to commence clinical studies for the products in the United States.
Clinical studies are being scheduled for 2nd Quarter of this year to
support the FDA pre-market clearance (510k). A study we conducted in
collaboration with the CDC that was published in December in the
Journal of Clinical Microbiology, as well as studies reported by CDC
confirm the value of our multiplex DPP® Syphilis Screen & Confirm
test.
-- China Evaluation - Through our ongoing collaboration with the CDC for
this product, we were invited by the WHO Collaborating Center in
China to conduct a training session there in January for a multi-site
evaluation of this product which is starting now and that is
scheduled to be completed during the second quarter. Our DPP®
patent was just issued in China, where syphilis is on the rise, and
we have begun to consider various opportunities for distribution and
manufacturing of our products there, including but not limited to
this product.
-- CE Mark - When we are ready to begin the clinical studies for this
product we will alos be able to submit this product for
self-certification of a CE Mark, which submission we anticipate
filing in the 2nd quarter 2011.
-- FIOCRUZ Programs - We have five active projects with FIOCRUZ, four
relating to agreements signed in 2008 and one (Syphilis) signed in
2010.
-- Approval of DPP® HIV Screening and Confirmatory Assays - During
2010 ANVISA granted FIOCRUZ approval to market our DPP® HIV 1/2
Screening and Confirmatory Tests. We believe the Ministry of
Health in Brazil is seeking to have these products used in a new
serial testing algorithm to be deployed nationally, and that an
evaluation concerning this new algorithm is ongoing.
-- DPP® Canine Leishmaniasis - In January 2011 FIOCRUZ was requested
by MAPA for the second time to provide additional information.
This will further delay the approval process and based upon recent
experience it is difficult to predict timing. Nevertheless, based
on our discussions with FIOCRUZ, we believe there remains strong
support for this product within FIOCRUZ and that they are
continuing their efforts in prosecuting the approval of this product
by MAPA.
-- DPP® Leptospirosis - Chembio sent three production lots of this
product to FIOCRUZ and FIOCRUZ is completing the preparation of a
technical file in order to submit to ANVISA for approval. FIOCRUZ
estimates ANVISA approval will be granted during the second quarter
of 2011.
-- DPP® Syphilis Treponemal - Chembio sent three production lots of to
FIOCRUZ and FIOCRUZ is completing the preparation of a technical
file in order to submit to ANVISA for approval. FIOCRUZ estimates
ANVISA approval will be granted during the second quarter of 2011.
We also had significant progress on the following projects in 2010
-- Bio-Rad Laboratories OEM Multiplex DPP® Agreement - In June 2010
Bio-Rad confirmed that the product development activity had been
completed in accordance with the agreed-upon specifications,
resulting in a license fee being earned. At that time Bio-Rad also
exercised its option to have Chembio transfer the manufacturing of
this product to Bio-Rad, which process was also satisfactorily
completed, in October 2010, resulting in additional agreed-upon
fees being earned. We believe that Bio-Rad will begin to market
this product in Europe beginning in 2012, and in the United States
in 2013, although there can be no assurance of this. During 2010,
Chembio earned approximately $128,000 for product development work
rendered to Bio-Rad under this agreement, plus an additional $615,000
in license and other fees related to the manufacturing transfer.
-- Battelle/CDC DPP® Multiplex Influenza Immunity Test - In
December 2009 Chembio entered into a milestone-based development
agreement for the development and initial supply of a multiplex,
rapid point-of-care ("POC") influenza immunity test. During 2010
development work with respect to the contract development
specification was substantially completed. Our contract partners are
assessing the prototype product and determining potential additional
funded development activity. During 2010, Chembio earned approximately
$804,000 in milestones for product development work rendered under
this agreement.
-- DPP® Influenza - We have developed a prototype multiplex test for
FLU A/B Antigen Detection and plan to complete R&D development for
this test in March 2011 and to complete validation by the end of the
second quarter of 2011. We will submit our pre-IDE to 510K in July 2011
based on our current plan. This will help us to conduct clinical trials
during late 2011 and/or early 2012.
-- DPP® Leptospirosis Phase II Grant - In 2009 we were awarded a three
year, $1.9 million Small Business Innovative Research (SBIR) Phase II
grant from the United States National Institutes of Health (NIH) to
fully develop, validate, and commercialize a rapid diagnostic test for
Leptospirosis for general use worldwide, and our work is progressing
on schedule. To date, we have identified several novel leptospiral
proteins cloned from a variety of strains that are prevalent in
different countries. These antigens will supplement the current test
prototype and thus enhance the potential for its use worldwide as a
universal point-of-care test for leptospirosis.
-- DPP® Tuberculosis Phase II Grant - In February 2011 we were awarded
an SBIR Phase II grant from the NIH to continue development of a simple,
rapid, accurate, and cost-effective serological test for active
tuberculosis that can be utilized in resource-limited settings.
Chembio developed a prototype of this test in the Phase I work in
collaboration with the Infectious Disease Research Institute ("IDRI"),
a Seattle-based biotechnology research organization dedicated to
technologies that address diseases in the developing world; this
collaboration will continue in this second phase of the research and
development grant as well. The grant is effective March 1, 2011. The
prototype test developed during the Phase I work uses the Dual Path
Platform (DPP®) technology together with selected antigens from a
large panel of novel recombinant antigens identified at IDRI. The
Phase I studies demonstrated the feasibility of developing a rapid
and accurate test for tuberculosis with required diagnostic
performance characteristics (sensitivity > 80%, specificity > 95%).
In Phase II, the proposed rapid (15 minutes) point-of-care DPP® test
for tuberculosis will be fully developed, optimized, and evaluated
in multi-center clinical trials in several countries, followed by
validation of production protocols, preparation for regulatory
approval and commercialization
-- DPP® Hepatitis C - In 2010 we received data from a study sponsored by
the CDC that assessed the performance of our HCV product. The data,
which we believe will be published soon, confirmed that we had
achieved good performance with this HCV antibody detection test
prototype. We have recently been invited to participate in some
additional CDC studies this year with this and certain other
related prototype products that we have in development in this
area. We have also determined however that the market opportunity
for a point of care HCV antibody only (i.e., without antigen detection)
test is very limited, and so in addition to improving our antibody
detection test, we are also working on including antigen detection as
well as in a new DPP® format that we have in development, which format
incorporates some of our platform enhancements (see below). We believe
this could result in a more commercially viable market opportunity for
this market.
Other Activities & Developments
-- Platform Enhancements - During 2010 and increasingly during 2011
we are improving and enhancing the capabilities of our DPP®
technology. For example, we are further simplifying the procedure
to run certain kinds of tests developed with DPP® and we are also
making antibody and antigen detection available in a single test
device without certain limitations that exist when this is attempted
with lateral flow technology.
-- Operations - We have also fully integrated the new automated assembly
system into our manufacturing operation, which will make all of our
production, both lateral flow and DPP®, more cost effective.
-- Patents Issued & Pending - The Company has obtained patent coverage on
the DPP® product line, including three U.S. patents, and patents in
China, Malaysia, Eurasia, Mexico, Singapore, and the U.K. Additional
patents applications on the DPP® product line are pending in the U.S.,
as well as in many foreign countries such as Australia, Brazil, Canada,
the European Union, India, Indonesia, Israel, Japan, Korea, and
South Africa. Patents have also been filed on extensions to the DPP®
product line concept.
There can be no assurance that any of these projects will continue, meet regulatory or other technical requirements and specifications, and/or that if continued, will result in completed products, or that such products, if successfully completed, will be successfully commercialized.
Conference Call
Chembio has scheduled a conference call and webcast for 10:00 a.m. Eastern time on Thursday, March 3, 2011. To participate on the conference call, please dial (877) 407-0778 from the U.S. or (201) 689-8565 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until March 10, 2011 at 11:59 p.m. Eastern Time by dialing (877) 660-6853 from the U.S. or (201) 612-7415 from outside the U.S. and entering reservation account number 286 and conference ID #: 36779. The conference call may also be accessed via the internet at http://www.investorcalendar.com/IC/CEPage.asp?ID=163520. An archive of the webcast will be available for 90 days on the Company's website at www.chembio.com.
Investor Presentation
The Company has prepared and filed a new investor presentation. It can be accessed through the following link: http://phx.corporate-ir.net/phoenix.zhtml?c=121584&p=irol-IRhome.
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $7 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Inverness Medical Innovations, Inc. Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP®. Headquartered in Medford, NY, with approximately 100 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485.
CTEI, TPIV...both stocks have recently seen activity that strongly suggests we will see a continuation of the existing trend, which is UP.
TPIV-$.33...1yr chart-8mo of range bound trading around .15 and now moves up and out--volume confirms breakout-
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=tpiv&insttype=&freq=1&show=True&time=8
CTEI-$.30...6mo chart again with multi month range bound trading and then the breakout-
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=ctei&insttype=&freq=1&show=True&time=7
Each stock is moving for its own reasons and trend look to stay intact...
ZBB $1.28 up .08 v 330,000...has a PR out this morning and among all the storage/battery tech stocks out here I think I have seen ZBB rec'd first among equals in any number of places....and note the headline alone here for today's PR--->>below-then what they do>>>>there is no way alt energy sources are going make it to the national grid, which needs replacing on its own accord--without companies like ZBB helping to handle and store the power...
ZBB Energy to Provide Energy Storage for Army's Micro-Grid Project
ZBB Awarded Contract From Eaton Corporation to Deliver 500kWH Energy Storage System to Fort Sill, Utilizing ZBB's Next Generation ZESS V3 Zinc Bromide Flow Battery
ZBB Energy Corporation develops, manufactures, and markets energy storage systems for utility companies, and commercial and industrial customers. Its energy storage solutions are based upon its proprietary zinc-bromine rechargeable electrical energy storage and power management technologies. The company?s systems combine its zinc-bromine batteries with computer hardware and software that interface with a customer?s power source to recharge during off peak times and discharge power as needed. ZBB Energy Corporation markets its products under the trade names of ZESS 50, ZESS 500, and ZESS POWR. Its systems are used in various applications, including load management for generation, transmission, and distribution utilities; energy service companies; and commercial and industrial customers, as well as for the storage of renewable energy, such as wind and solar energy production in both grid connected and grid independent environments. These systems are also used for the uninterruptible power supply and power quality protection from voltage, current, or frequency deviations. The company was founded in 1981 and is based in Menomonee Falls, Wisconsin.
INX.v, INXSF.pk...FORECAST IS FOR 25% RISE IN REV FOR 2011..
...talked with mgmt last week and was impressed by first the new website which CEO thinks gets across their capabilities in the new MOBILE world in a more defined manner as linked with their patented technologies for data capture.
They are now being followed by Globalstockiq.com AND very soon now there is going to be a research report out on this company which should open some eyes and wallets about the future of the mobile world and INX's place in that world.
If you go to the new www site: www.intouchsurvey.com
You can get a better idea now of how their service intereconnect to serve their clients and why their business is beginning to throw off some large and larger numbers. The KEY factor about their ability to serve their clients so well IS THAT THEIR APPS CAN WORK ON ANY DEVICE OUT THERE, MORE AND MORE APPS ARE COMING AND THE MILITARY IS NOW BECOMING A LARGER PORTION OF THEIR BUSINESS. The fact that their business apps are ubiquitous may be something only they can provide--I think that may be the case but have to do more work on it.
The 4th qtr pre lim numbers are solid. Company sees increasing demand from Fortune 100 clients for specific apps for specific data mining purposes that should give them the forecast they described for the year already begun. I have stated before that I think this stock is grossly undervalued esp given their much stronger numbers and forecast AND the increasing use of their apps by commercial and military alike--and more apps coming. I think their presence in the mobile world is growing quickly and at .35 per sh investors with patience are getting a helluva deal. My near tern forecast for the stock is 1.00 end of June and if thinks remain in trend then possibly 2.00 by year end--if not more. I don't see anything out there right now that could hurt then except a general economic slowdown and that is not in the cards. 10k should be out within days and there should be add'l new then. gpg
Press Release Source: IN-TOUCH SURVEY SYSTEMS LTD. On Monday January 31, 2011, 4:00 pm EST
OTTAWA, Jan. 31 /CNW/ - In-Touch Survey Systems Ltd. ("In-Touch" TSX-Venture: INX) announces preliminary financial results for Q4 2010, and FY 2010. The Company begins its 2010 audit at the end of February and final results will be released once the audit is complete and the Board of Directors approves the Financial Statements.
Revenue increased 9% to approximately $1,500,000 in Q4 2010 compared to $1,381,506 in Q4 2009. The Company expects net earnings for Q4 2010 of approximately $140,000, an increase of 163% compared to a loss of $222,913 in Q4 2009. The Company-defined adjusted EBITDA increased 90% to approximately $300,000 in Q4 2010, compared to an EBITDA of $157,000 in Q4 2009.
Annual revenues for 2010 are expected to exceed $5,800,000, an increase of 7% compared to revenues of $5,479,081 for FY 2009. Annual net income increased approximately 160% to $700,000 compared to a loss of $440,377 last year. EBITDA of approximately $1,200,000, an increase of 410%, was realized for the year compared to $293,000 for 2009.
"We are very pleased with our 2010 financial and business performance. The turmoil of the 2008-09 recession and meltdown in the financial sector was a major business challenge. I credit our strategy, our customers, but most of all the resiliency of our employees to fight through the challenges and deliver these exceptional results", said Michael Gaffney, Chief Executive Officer.
"Fiscal 2011 revenue targets are on track to more than triple the 7% growth rate of 2010 and we anticipate 2011 revenues to be at least 25% higher than 2010", said Gaffney.
On January 25, 2010, the Company granted options to purchase up to 260,000 common shares at an exercise price of C $0.20 per share to employees and officers of the Company pursuant to the Company's stock option plan. The options granted are valid until January 24, 2014. These grants are subject to regulatory approval. The Company's stock option plan expires August 31, 2013.
Certain statements included in this news release contain forward looking statements, which by their nature are necessarily subject to risks and uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such statements reflect the Company's current views with respect to future events, and are based on information currently available to the Company and on hypotheses which it considers to be reasonable; however, management warns the reader that hypotheses relative to future events which are beyond the control of management could prove to be false, given that they are subject to certain risks and uncertainties.
The TSX Venture Exchange has not reviewed the foregoing and has neither approved or disapproved the contents of this press release.
To view this news release in HTML formatting, please use the following URL:
http://www.newswire.ca/en/releases/archive/January2011/31/c6525.html
yoda---take a look at TSTA...I know them inside out, all senior mgmt, and they are going to start kicking up some dust real soon....you can't buy at this price often-.43, and by June I think we will be back above a buck....MC...
CTEI vol is 95,000...more than 2x normal...take note of following--->>>price at .33--
# Cemtrex Outlook: EPA's MACT Regulation Will Have a Positive ImpactPR Newswire(Fri 10:00AM EDT)
# Cemtrex Completes Installs of Green DCV System at Aerospace CompanyPR Newswire(Tue, Mar 1)
# CEMTREX INC FinancialsEDGAR Online Financials(Sat, Feb 26)
# Cemtrex Reports First Quarter Results: Sales Increase by 104%PR Newswire(Wed, Feb 23)
# Griffin Filters Secures $8.0 Million Order for Equipment Supply on a Power ProjectPR Newswire(Wed, Feb 9)
ENSV.ob..$.89.there is another aspect to this play that just doubles down my interest and conviction that I have landed a long term winner. Take a look at this chart. I can't be sure but am going to find out over this w/e why the drastic fall in Nov of '09. I think it was due to fact that this is when ASPN announced to investors that they were going to sell off their CA nat gas properties and distr to stockholders. Not certain but does make sense and will find out.
Regardless of HOW it was formed we have a Ferrari formation here for ENSV with multi months-6mo-at .30 and then the breakout to a spike of 1.00, then some churning and testing on new range and then the next leg up was has taken us up to .89. I set my price predictions out yest for short term moves and this chart makes it all the more certain my targets will be achieved.
Chart-
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=ensv&insttype=&freq=1&show=&time=9
CTEI, a good epa play and i think we will hear more results of their efforts overseas. up 104% last Q.
CEMI...$.49...a couple things to note here--first is that they are a penny away from 52wh of .50. Second is their year end which is chock full of interesting news and info all of it good. below.
Third is this chart which has a dual Ferrari formation...unusual to see but all the more powerful IMO. Here is a 1 year chart-note the 6mo of RBT at .25 level then the pop and then the 4mo RBT around .40/.45 and the recent pop up from there. Vol is 175,000 now and it looks to me as tho CEMI is ready to GO--->>
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=cemi&insttype=&freq=1&show=&time=8
Q4 2010 Financial Results
Chembio (CEMI.OB) reported results for the fourth quarter and full year ending December 31, 2010, on March 3, 2011. Fourth quarter revenue of $5.67 million was about 6% better than our $5.33 million estimate and was up 59.6% y-o-y. For the full year revenue came in at $16.7 million, representing growth of almost 21% compared with fiscal 2009. Revenue in Q4 and for the full year marked all-time highs for both periods.
Growth in sales of Chembio’s lateral flow products, both in the U.S. and overseas continues to be very strong and was a big contributor to the record revenues. We expect lateral flow sales to remain robust through at least all of 2011 as increased funding from international testing programs helps drive demand in areas such as Africa and South America and further implementation of (and compliance with) CDC HIV testing recommendations benefits domestic sales.
Q4 EPS of $0.03 on net income of $1.88MM was better than our $0.00 and $246k estimates and was up from $0.00 and $217k in Q4 2009. For the full year 2010 EPS was $0.04 on net income of $2.51MM versus $0.00 and $309k in fiscal 2009. Q4 (and full year) 2010 results significantly benefitted from the $1.47MM Qualifying Therapeutic Discovery Projects (QTDP) program grant that Chembio was awarded and received in October 2010. This $1.47MM was accounted for as a reduction to R&D expense in the most recent quarter. Chembio expensed approximately $130k in Q4 related to exploring potential buy-out offers (at least one of which was unsolicited). This is in addition to $143k that was expensed for the same purpose in Q3.
Pro forma (our calculation) for the QTDP grant (and related taxes) and expenses related to potential M&A, Q4 and full year 2010 net income and EPS were approximately: $579k, $0.01 and $1,355k and $0.02 – the pro forma net income figures still representing all-time record highs on both a quarterly and annual basis.
Full Year Revenue highlights
Product sales up 9% y-o-y to $13.52 million in 2010 – an all-time high
* HIV lateral flow sales to Alere were flat y-o-y but likely under-representative of true demand due to inventory stocking
* International HIV lateral flow sales grew 23% y-o-y, including 63% during the second half
* Product sales; $6.3MM (2006), $8.8MM (2007), $10.4MM (2008), $12.4MM (2009), $13.5MM (2010), $18.9MM (2011 E)
License & Royalty income $433k in 2010, versus $122k in 2009
* 2010 included $340k milestone related to Bio-Rad multiplex product
R&D Contracts, Grants, Milestones revenue was $2.76MM versus $1.34MM in 2009
* NIH Leptospirosis and Battelle/CDC Flu milestones were significant contributors to R&D revenue in 2010
Cash
$2.14MM at year end 2010 versus $1.07MM at year end 2009
* A/R ended the year at $3.95MM, up from $1.78MM at year end 2009. A significant portion of this elevated A/R balance will be collected in early 2011 (including $846k that had yet to be collected from the QTDP grant). This will result in substantial additional cash
* Operating cash flow was $1.02MM in 2010 compared to $252k in 2009. Stripping out the $620kMM received during the year related to the QTDP grant and changes in working capital (net of the $846k addition to A/R related to the portion of the QTDP grant yet to be collected), operating cash flow was approximately $1.52MM in 2010 – which is more representative of Chembio’s fundamental cash flow in the year
* The only debt consists of $242k drawn on a bank facility
* Chembio made final payment ($875k) to Bio-Rad in January 2011 relative to their HIV 2 licensing agreement
We think Chembio can be operating cash flow positive from here on out and believe any risk of shareholder dilution is now minimal
Q4 2010 Business Update
M&A – at end of Q3 management revealed two potential suitors were investigating making an offer for Chembio. Q4 press release and conference call Chembio management noted these potential deals will not happen.
Chembio was granted a 3-year $2.7MM grant for phase II funding of a DPP tuberculosis test
Product Update
DPP HIV, U.S.
Clinical trials are about ½ way done. CEMI is shooting for completion in summer 2011. CEMI submitted request to FDA in early March 2011seeking a modular PMA regulatory filing. If granted, it will provide for filing in 3 subsequent tranches and allow CEMI to file preclinical and manufacturing data as clinical data continues to be collected. CEMI's current expectations are for filings during Q1, Q2 and Q3 2011.
Impact to our model: The U.S. DPP HIV trials have been drawn out longer than initially anticipated. Prior to this latest update we had modeled the DPP HIV test to launch in the U.S. in Q2 2012. We now think this is unlikely and now model the launch in Q4 2012.
DPP Syphilis
Clinical trials in support of 510(k) expected to start during Q2 2011. CEMI expects to submit for self-certification for CE Mark at that time so launch in Europe could come in Q2 2011. Chembio also noted that it has been invited by the WHO Collaborating Center in China to evaluate their DPP syphilis test in a multi-site program.
Impact to our model: We had previously modeled U.S. launch to happen in Q4 2011. We now look for U.S. launch in Q2 2012. Europe launch timeline remains in-line with our prior forecast.
DPP Flu A/B
CEMI expects to complete development in March 2011 and validation by end of Q2 2011. Hope to submit pre-IDE to 510(k) in July 2011 and start clinical trials in Q4 2012.
Impact to our model: We were previously shooting for launch in Q4 2011 – now pushing this back to Q4 2012 (allowing for possible delays).
DPP HCV Antibody
CEMI determined market for just an HCV antibody test (without antigen) is too limited – will pursue product combining both antibody and antigen detection into one test.
Impact to our model: Not overly significant. Had previously modeled launch in Q3 2011 but with relatively little revenue. Now pushing this back to Q1 2013.
DPP Canine Leishmaniasis (FIOCRUZ)
In January 2011 FIOCRUZ was requested to provide more information to MAPA (Ministry of Agriculture). CEMI did not provide visibility on timelines.
Impact to our model: We had modeled approval and launch in Q1 2011 although this delay affects our model immaterially as we had not expected a significant overall contribution from this test.
DPP Leptospirosis (FIOCRUZ)
Expect FIOCRUZ will file for regulatory very soon – expect approval in Q2 2011.
Impact to our model: Remains roughly in-line with our expectations.
DPP Syphilis Treponemal
CEMI recently sent three production lots to FIOCRUZ and FIOCRUZ is preparing a filing. Expect to receive approval in Q2 2011.
Impact to our model: Remains roughly in-line with our expectations.
OUR 2011 OUTLOOK
Revenue
We look for 2011 revenue of $20.7 million, implying growth of 23.8% from 2010. We expect much of this growth to be driven by acceleration in sales of DPP HIV test sales to FIOCRUZ. We also expect continued strong demand for Chembio’s lateral flow products which we model to post 13.8% sales growth in 2011. Meanwhile, contributions from both licensing income and R&D revenue will likely fall in 2011 compared to 2010 (we model $1.75MM in 2011 from $3.19MM in 2010) as the bulk of the majority of the high dollar contracts have already been received.
Net Income / EPS
We model Chembio to post net income of $1,310k and EPS of $0.02 in 2011, compared with $1,355k and $0.02 in 2010 (pro forma for the QTDP grant and M&A expenses). Despite our expectation that revenue will grow by almost 24% in 2011, due to higher R&D expenses (largely associated with U.S. DPP HIV clinical trials) much of this revenue will not flow through to the bottom line.
Cash
Most importantly, this expected level of revenue, combined with Chembio’s already sizeable cash balance ($2.14MM at 12/31/2010 but which should be even higher at 3/31/2011), should be more than sufficient to fund all operations (including clinical trials, regulatory filings, SG&A, etc.). We fully expect, based on our current model, that Chembio will be operating cash flow positive for the full year 2011 (although certain quarters may not be, i.e. – Q1 and Q2) and beyond and will not need to tap additional financing for the foreseeable future.
RECOMMENDATION / VALUATION
Valuation
We are maintaining our Outperform rating of Chembio Diagnostics with an Outperform rating. Based on the potential for the DPP product portfolio to significantly ramp long-term revenue, cash flow and earnings we continue to feel the company is grossly undervalued.
We value Chembio based on comparable price/sales ratio of 3.7x 2011 sales. We look for Chembio to post sales of $20.7MM in 2011 which values the company $76.6MM or $1.10 per share.
Sorry-that should have been CTEI...now at .32 and looking even better on chart.
CTIE--look at this chart going back 6mo...you have 4mo of range bound trading then the break higher...this is usually good for many multiples from the breakout price..anywhere from 10-20x.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=ctei&insttype=&freq=1&show=&time=7
CTEI, TSTA....this came over CTEI's wire but will positively affect both companies in the next 8-12 qtrs___>>>
Cemtrex Outlook: EPA's MACT Regulation Will Have a Positive Impact
FARMINGDALE, N.Y., April 1, 2011 /PRNewswire/ -- Cemtrex Inc. announced
today that the EPA is expected to issue new regulations for air pollution
emissions from electrical generating units (EGUs) based upon the Maximum
Achievable Control Technology (MACT) provisions of the Clean Air Act Amendments
in March 2011. The final regulations should be promulgated by November 2011 and
then power plants will have 36 months to comply.
This final rule covers nearly all boilers that burn coal, oil, or
biomass, or non-waste materials, but exempts boilers that burn only gaseous
fuels or any solid waste. According to EPA estimates, there are about 187,000
existing area source boilers at 92,000 facilities and about 2,400 new area
source boilers will be installed over the next 3 years. The vast majority of
area source boilers shall have to comply with this MACT regulation.
"With this new rule we anticipate an enormous increase in the
opportunities for Cemtrex to pursue in the domestic market," said Saagar
Govil, Vice President of Operations at Cemtrex. "By our estimates, we think
there will be at least 2000 CEMS (Continuous Emission Monitoring Systems)
opportunities over the next three years as a result of this new EPA standard,
which we are working hard to capitalize on," continued Mr. Govil.
Cemtrex has a complete suite of analyzers and reporting systems for
facilities to utilize to meet EPA requirements of this rule. Cemtrex's Boiler
Compliance System consists of Mercury, Hydrochloric Acid, Particulate Matter,
and Carbon Monoxide, which has been combined in an innovative system
specifically for these compliance requirements.
Cemtrex Inc. is a worldwide market leader in manufacturing and selling
the most advanced instruments for emission monitoring of particulate, opacity,
mercury, sulfur dioxide, nitrogen oxides, etc. and filtration products for the
industry. Cemtrex also markets Green DCV, a innovative energy efficiency
solution for high-quality green building applications, through optimizing HVAC
control systems. Cemtrex provides technologies and services for abatement of
greenhouse gases pursuant to the Kyoto protocol and assists customers in
creating and selling carbon credits from such projects. The Company's products
are sold to power plants, refineries, chemical plants, cement plants and other
industries, including federal and state governmental agencies.
Safe Harbor Statement
This press release contains forward-looking statements; Actual results
could differ materially from those projected in the forward-looking statements
as a result of a number of risks and uncertainties. Statements made herein are
as of the date of this press release and should not be relied upon as of any
subsequent date.
For further information please contact:
Cemtrex Inc.Contact: Saagar GovilEmail:
sgovil@cemtrex.comhttp://www.cemtrex.com/
Cemtrex Inc.
CONTACT: Saagar Govil, Cemtrex Inc., +1-631-756-9116,
CTEI .29...52wh $.35...this is starting to look real interesting--chart-->>
http://stockcharts.com/h-sc/ui?s=ctei
-$8m order last month-->>order from INDIA-BRIC country-->>
Griffin Filters Secures $8.0 Million Order for Equipment Supply on a Power Project
Press Release Source: Cemtrex Inc. On Wednesday February 9, 2011, 10:00 am EST
FARMINGDALE, N.Y., Feb. 9, 2011 /PRNewswire/ -- Griffin Filters, a subsidiary of Cemtrex Inc. (OTCQB: CTEI), announced that it has received an order, valued at approximately $8.0 million, to supply environmental control equipment on a power project in India. The Company expects to ship this order within the current fiscal year.
"We are finally seeing the results of our tremendous marketing efforts in Asia during the past year," said Mr. Saagar Govil, V.P. Operations of Cemtrex. "Due to numerous power projects coming up in India and China, we are hopeful of securing more such business in the coming months."
Griffin Filters (http://www.griffinfilters.com) is a wholly owned subsidiary of Cemtrex Inc. (http://www.cemtrex.com) and has been a leader in fabric filter dust collection and other environmental control products for over 40 years. It offers standard filters for the concrete, aggregate and construction industries and custom-engineered environmental control systems for a wide variety of industries such as cement, plastics, chemical, power, steel, food and minerals. Griffin offers an unusually large selection of equipment, which gives it the ability to match the widest range of application needs, whether solids processing, product recovery or air pollution control.
1st qtr--rev up 104%, $144,217 profit vs ($32,000) loss...
FARMINGDALE, N.Y., Feb. 23, 2011 /PRNewswire/ -- Cemtrex Inc. (OTC:CTEI.ob - News) today announced its first quarter consolidated results of operations for the three months ended December 31, 2010.
First Quarter Highlights:
* Revenue increased by 104% to $1,821,634 in first quarter ended December 31, 2010 compared to $891,454 in first quarter ended December 31, 2009.
* Net Income was $144,217 in first quarter ended December 31, 2010 compared to a loss of $32,006 in first quarter ended December 31, 2009.
Commenting on the quarterly results, Mr. Arun Govil, President and Chief Executive Officer of the Company, remarked, "We are pleased with this turnaround to profitability, and would like to thank our employees for their efforts, which have resulted in enhanced global marketing efforts, securing large projects in the international marketplace, and overall effective execution."
"We are confident in our ability to secure more such projects and create sustainable profitability for the long term," continued Mr. Govil.
Cemtrex Inc. through its subsidiaries is a worldwide market leader in manufacturing and selling the most advanced equipment and systems for stack gas emission monitoring, air filtration and other environmental control products in a wide variety of industries, including power plants, refineries, chemical, steel and cement plants. Cemtrex also markets Green DCV, an innovative energy efficiency solution for high-quality green building applications, through optimizing HVAC control systems.
ENSV.ob...$.73--52wh $.99---...there are a number of points in the year end which in my opinion make ENSV a diamond in the rough as well as an unknown rising star. I will delineate some of the more salient features of the report which is below in its entirety-
-Fourth quarter revenue advanced 61% to $6.0 million from $3.7 million in the 2009 fourth quarter. Company states strength due to success of geographic expansion (which continues as we speak), increase in demand for fracking services (which will continue to explode in terms of fracking being used to unlock nat gas in the shale as nat gas and coal become more in demand post Japan)and increase in contracts due to demand from new finds.
-ENSERVCO reduced its fourth quarter operating loss to $41,000 from $1.0 million in the 2009 fourth quarter. The Company achieved a positive bottom-line swing of $2.9 million, reducing its net loss to $163,000, or $0.01 per diluted share on 21,779,000 weighted average shares outstanding. Company increased velocity thru last few qtr to qtr periods and ended 4th with numbers really swinging their way.
-Revenue for the full 2010 fiscal year increased 21% to $18.6 million from $15.4 million in 2009. Adjusted EBITDA* increased 388% to $2.0 million from $414,000 during the prior year. Loss from operations declined to $2.3 million from $4.0 million in 2009. Full-year net loss declined to $1.8 million, or $0.10 per diluted share on 17,642,000 weighted average shares outstanding, from $5.9 million, or $0.41 per diluted share on 14,519,000 weighted average shares outstanding, in 2009. You can see that by the 4th qtr things were really turning around and in talking with the company that momentum is intact as indicated in the latter part of the PR.
-"The results of our 2010 expansion into the Northeast United States exceeded our expectations," said Mike Herman, chairman and chief executive officer. "We initiated operations in the Marcellus Shale region during the first quarter of 2010 to address the needs of a large existing customer. By the fourth quarter, we were serving 12 major exploration and production companies in the region. We now have a strong foothold in what has become one of North America's most active natural gas basins, and we are currently working to further expand our customer base and add services that will be counter seasonal to our heating operations."
Expansion geographically continues as does investment into more equip as company finds its services in greater and greater demand.
-current plans call for aggressive move into new finds to continue as demand for their scvs continue to mount-"Going forward, geographic expansion will remain one of our primary growth strategies. We are aggressively expanding our current operations in the Niobrara shale in eastern Wyoming, where state lease sales are commanding record valuations and there is intense competition among producers that are vying to drill in the formation. In addition, we continue to pursue opportunities in the active Bakken formation in North Dakota.
FINALLY, THIS IS WHAT YOU WANT TO SEE WHEN YOU KNOW YOU HAVE FOUND A PLAY NOBODY SEEMS TO KNOW ABOUT-the progress that attracted you to the play is not only going to increase but accelerate--->>>"Perhaps our most significant challenge in recent months is that customer demand has outstripped the availability of our well-site service equipment. Where possible, we have redeployed assets and personnel to more optimal locations, but we are also working to accelerate the construction of new trucks and equipment. Finally, we are actively evaluating opportunities to add new services that could augment our revenue stream and help mitigate the seasonality of our fluid heating business."
Rick Kasch, chief financial officer, said the Company is off to a strong start to fiscal 2011. "January represented a new monthly record for revenue, and given the favorable environment for the domestic oil and gas industry and our aggressive growth strategy, we are optimistic we will see continued improvements in our financial performance throughout 2011."
AND, Japan has turned the world upside down. I believe you could sit at your computer and invest in coal and nat gas stocks for the next 5 years and make a killing if you learn enough about the business. Demand for ENSV is going to continue to grow-so are they and this year my best guess is that the company is going to earn $.25-$.35 per sh--maybe more.
My level of confidence in this play is solid. gpg
====================
PR year end--
Well-Site Service Provider ENSERVCO Reports Fourth Quarter Financial Results; Revenue Increases 61% to $6.0 Million, Adjusted EBITDA Improves to $1.1 Million
marketwire
Press Release Source: ENSERVCO On Monday March 28, 2011, 7:00 am EDT
COLORADO SPRINGS, CO--(Marketwire - 03/28/11) - ENSERVCO Corporation (Pinksheets:ENSV - News) (Pinksheets:ENSV - News) a provider of well-site services to the domestic onshore oil and gas industry, today reported financial results for the fourth quarter and fiscal year ended December 31, 2010.
Fourth quarter revenue advanced 61% to $6.0 million from $3.7 million in the 2009 fourth quarter. Adjusted EBITDA* increased to $1.1 million versus negative $10,000 in the 2009 fourth quarter. Management said the growth in revenue and adjusted EBITDA was attributable to strong seasonal demand for ENSERVCO's fluid heating services, the positive impact of the Company's geographic expansion and a rebound in domestic onshore drilling activity.
ENSERVCO reduced its fourth quarter operating loss to $41,000 from $1.0 million in the 2009 fourth quarter. The Company achieved a positive bottom-line swing of $2.9 million, reducing its net loss to $163,000, or $0.01 per diluted share on 21,779,000 weighted average shares outstanding, versus a net loss of $3.0 million, or $0.21 per diluted share on 14,519,000 weighted average shares outstanding, in the fourth quarter of 2009.
Revenue for the full 2010 fiscal year increased 21% to $18.6 million from $15.4 million in 2009. Adjusted EBITDA* increased 388% to $2.0 million from $414,000 during the prior year. Loss from operations declined to $2.3 million from $4.0 million in 2009. Full-year net loss declined to $1.8 million, or $0.10 per diluted share on 17,642,000 weighted average shares outstanding, from $5.9 million, or $0.41 per diluted share on 14,519,000 weighted average shares outstanding, in 2009.
"The results of our 2010 expansion into the Northeast United States exceeded our expectations," said Mike Herman, chairman and chief executive officer. "We initiated operations in the Marcellus Shale region during the first quarter of 2010 to address the needs of a large existing customer. By the fourth quarter, we were serving 12 major exploration and production companies in the region. We now have a strong foothold in what has become one of North America's most active natural gas basins, and we are currently working to further expand our customer base and add services that will be counter seasonal to our heating operations."
"We also are encouraged by the progress we made in several of our core markets," Herman added. "In recent months, we have added several new customers in the Rocky Mountain region, where we anticipate we could see meaningful long-term growth. We believe our success at building market share in a competitive environment reflects the strength of our equipment portfolio and our reputation for outstanding customer service.
"Going forward, geographic expansion will remain one of our primary growth strategies. We are aggressively expanding our current operations in the Niobrara shale in eastern Wyoming, where state lease sales are commanding record valuations and there is intense competition among producers that are vying to drill in the formation. In addition, we continue to pursue opportunities in the active Bakken formation in North Dakota.
"Perhaps our most significant challenge in recent months is that customer demand has outstripped the availability of our well-site service equipment. Where possible, we have redeployed assets and personnel to more optimal locations, but we are also working to accelerate the construction of new trucks and equipment. Finally, we are actively evaluating opportunities to add new services that could augment our revenue stream and help mitigate the seasonality of our fluid heating business."
Rick Kasch, chief financial officer, said the Company is off to a strong start to fiscal 2011. "January represented a new monthly record for revenue, and given the favorable environment for the domestic oil and gas industry and our aggressive growth strategy, we are optimistic we will see continued improvements in our financial performance throughout 2011."
About ENSERVCO
Through its two operating subsidiaries, Heat Waves Hot Oil Service and Dillco Fluid Service, ENSERVCO has emerged as one of the energy service industry's leading providers of hot oiling, acidizing, frac heating and fluid management services. The Company owns and operates a fleet of more than 200 specialized trucks, trailers, frac tanks and related well-site equipment. ENSERVCO operates in Colorado, Kansas, New Mexico, Oklahoma, Pennsylvania, Texas, Utah and Wyoming. ENSERVCO became a public company in July 2010 when it merged with Aspen Exploration Corporation, which is now doing business under the trade name ENSERVCO Corporation. Additional information about the Company is available at www.enservco.com.
MIMV.OB .70-HERE IS NEW POST ON MIMV FOLLOWED BY MY PRIOR POST--BOTH CONTAIN THE INFORMATION YOU NEED TO RECOGNIZE THAT THIS IS A DARK HORSE PLAY WITH TANTALIZING ODDS TO WIN THE BIG RACE AND GARNER ALL THE MONETARY REWARDS THAT ACCOMPANY SAME IN THE MOBILE TSUNAMI THAT IS UPON US-WE WILL BE AN APP WORLD-EVERY PERSON PLACE THING WILL HAVE AN APP WORLDWIDE AND MIMV HAS THE TECHNOLOGY/PATENTS TO SEARCH OUT THOSE APPS ANYONE IS LOOKING FOR FOR ANY REASON...AND PLACEMENT OF SAME WILL BE AL LA GOOGLE IN THAT BETTER THE APP IS PLACED IN THE DIRECTORY THE BETTER THE MONETARY BENEFIT TO MIMVI--IT'S ALL DOWN BELOW HERE--A SINGULAR OPPORTUNITY IN THE COMING MOBILE WORLD.
TODAY'S POST--->>>
MIMV.ob .70...GLUU has a pr out this am ref a new Android app. I intro'd MIMV because it has a shot at becoming the app for apps---read what is in the posts below and you will see what i mean. I would read it all as I do not think this play will go undiscovered for much longer. And you need to go to their site.
So get up to date here-
http://siliconinvestor.advfn.com/boardsearchresults.aspx?boardnum=50570&SrchStr=mimv
And then read thru these below...always keeping in mind the MIMV business plan. I think this will happen in one of the 2 following scenarios-
-some newsletter or site or small cap/microcap analyst will find MIMV and get things rolling...and this would probably be a more or less organized run up the price pole OR because the flt is so thin right now somebody discovers it and with modest effort gets some volume into the play that shortens up the spread plus gets a large % move that will be picked up on scans and then mania ensues and off we go. All that has to happen one way or the other is that investors discover what MIMV is all about in the MOBILE TSUNAMI on its way with APPS becoming an everyday thing for people, places, things--worldwide everyone and everything will have an APP. Different of course but it's going to go that way...more ubiquitous than sites by a factor of who knows how much....that is what all the reading is about...to try and nail down the opportunity. I think it's there and to get this play at this price even if an investor uses only gambling money I think a winning hand is almost in the bag....if not a royal flush then at least a full house Aces over Kings. gpg alert
1. Firm sees apps driving 50% sales growth for Apple through 2012
"George Colony, founder and CEO of Forrester Research, made the predictions in an interview with Bloomberg." "Colony sees Apple's growth being driven by what he calls an "app Internet," where consumers and businesses rely on app for content and services, rather than the Web."
http://www.appleinsider.com/articles/11/03/24/firm_sees_apps_driving_50_sales_growth_for_apple_through_2012.html
2. Forrester founder sees trouble for 'web-centric' Google
"But Colony says the "app Internet" does not bode well for search giant Google, which he argues is based on an increasingly outmoded online advertising model." "If you’re too Web-centric right now, you’re in trouble,” he said. “Google’s business model is completely based on you going to the Web and clicking on a link and seeing an ad impression. In the app Internet world, all of that goes away.”
http://www.itworld.com/mobile-amp-wireless/141377/forrester-founder-sees-trouble-web-centric-google
3. Five Visionaries Sum Up The Future Of Search
"Today, however, all that is changing. We are expecting much more from our search experiences, driven largely by how those experiences look in different circumstances: launched from a smartphone, launched through an app or launched with a very specific intent in mind."
http://searchengineland.com/five-visionaries-sum-up-the-future-of-search-69877
4. How the mobile marketplace is changing the online space
http://www.bizreport.com/2011/03/how-the-mobile-marketplace-is-changing-the-online-space.html
5. RIM acquires mobile app tool developer tinyHippos [to save themselves]
http://www.reuters.com/article/2011/03/26/us-rim-acquisition-tinyhippos-idUSTRE72P1N620110326
=========================
PRIOR POST
MIMV.OB-$.90.....pay the wide spread...it's a pittance compared to where this is going....search engine for apps-every one and every thing worldwide will have its own app----
03/15/11Mobile App Search Company, Mimvi, Adds Satish Gupta to Advisory Board
# Mimvi Positioned for Mobile App Internet Expansion Into ChinaMarketwire(Tue, Mar 8)
# Mimvi Signs Deal With Intertrust to Develop Mobile & Search TechnologyGlobeNewswire(Wed, Dec 8)
# Mobile App Co., Mimvi, Launches the World's First Discovery Engine for Health AppsGlobeNewswire(Thu, Dec 2)
# Mimvi Launches Mobile App Search Engines for Apple iPhone, Google Android and BlackBerry SmartphonesGlobeNewswire(Thu, Nov 18)
# Mobile App Company, Mimvi, Launches Largest Recommendation Engine for Mobile GamingGlobeNewswire(Thu, Nov 11)
# Daiwa Quantum Capital, Led by the Former CEO of Sony, Joins Advisory Board of Mobile App Search Company, Mimvi, Inc.GlobeNewswire(Tue, Nov 9)
* Original MySpace Investor Joins Mimvi's Advisory BoardGlobeNewswire (Thu, Nov 4)
* NBT Research, LLC Issues New Research Report on Mimvi, Inc.GlobeNewswire (Thu, Nov 4)
* Mimvi, Inc. Announces Patent Filing for "Intelligent" Mobile App Search and Recommendation TechnologyGlobeNewswire (Wed, Oct 20)
Thursday, September 16, 2010
* Mimvi Announces the Availability of a New Video Interview With Company CEO and Chief Visionary Officer, Kasian FranksGlobeNewswire (Thu, Sep 16)
===========
http://www.mimvi.com/health
http://www.mimvi.com/games
We also have separate vertical engines for iPhone, Android and Blackberry:
http://www.mimvi.com/apple
http://www.mimvi.com/android
http://www.mimvi.com/blackberry
Here are some links that you might find interesting:
Forrester: The Mobile App Internet: Making Sense Of The 2011 Mobile Hysteria
http://blogs.forrester.com/john_mccarthy/11-02-28-mobile_app_internet_making_sense_of_the_2011_mobile_hysteria
Google CEO: Mobile Growing Faster Than “All Our Predictions” [VIDEO]
http://mashable.com/2011/02/28/schmidt-mobile-growth/
Google goes to war with Apple over mobile apps
http://www.theinquirer.net/inquirer/news/2012494/google-goes-war-apple-mobile-apps
SF Cron: "Mobile is the biggest platform war ever,"
http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2011/02/21/BUI01HOUH6.DTL&type=business
“The trend is crazy, it’s unbelievably fast. Faster than when Netscape took off.”
http://www.troymedia.com/2011/02/25/alberta-companies-creating-bleeding-edge-mobile-apps/
Bill Gates: Mobile Devices to Revolutionize Health Care
"without this mobile phone app these people would have died" Now how do they find this mobile phone app? This correlates directly with the mobile health app search vertical Mimvi is releasing.
http://www.mobiledia.com/news/76764.html
FastCompany: 500 Million People to Use Mobile Health Apps [Alone] by 2015 (bigger than Facebook)
http://www.fastcompany.com/1701769/mhealth-summit-wraps-reveals-booming-industry
Mimvi described as the "Google" for mobile apps
http://www.theipadguide.com/content/top-five-places-find-best-ipad-applications/7176729
"Mimvi is Like Google For Smartphone Apps and Games"
http://www.guidingtech.com/mobiles/mimvi-mobile-phone-apps-search/
seekingalpha: Huge Tech Growth Expected from Apps
http://seekingalpha.com/article/253865-huge-tech-growth-expected-from-apps
NYT: "products being built first as mobile apps, with the Web site as second priority"
http://www.nytimes.com/2010/11/11/technology/11photo.html
Sir Martin Sorrell says mobile apps are 'holy grail' for advertisers
http://www.telegraph.co.uk/finance/newsbysector/mediatechnologyandtelecoms/media/8327348/Sir-Martin-Sorrell-says-mobile-apps-are-holy-grail-for-advertisers.html
MarketWatch: Top 5 reasons to invest in the app eco-system
"Your mom, your tennis partner, your grocer, your career mentor and the used car salesman you met with your sister-in-law all have a new Android or iPhone and they ask you about apps everytime you see them." The app builders are important just like the web builders of the 90's, but it was the web search engines that became the most valuable
http://blogs.marketwatch.com/cody/2011/02/18/top-5-reasons-you-know-the-app-revolution-is-real
ERICSSON: Mobile apps will transform business and industries
http://www.4-traders.com/ERICSSON-A-445400/news/ERICSSON-A-Mobile-apps-will-transform-business-and-industries-13561196/
Mobile World Congress: Apps become key driver of smartphone market
http://www.v3.co.uk/v3/news/2274787/mwc-applications-smartphones
Mary Meeker: Mobile Internet Will Soon Overtake Fixed Internet
http://gigaom.com/2010/04/12/mary-meeker-mobile-internet-will-soon-overtake-fixed-internet/
Smartphones Outsell PCs
http://www.readwriteweb.com/archives/smartphones_outsell_pcs.php
Mobile apps use second only to messaging
http://www.intomobile.com/2011/02/15/mobile-apps-research
CNBC Video: Smartphone Smackdown - Based on the Apps
http://finance.yahoo.com/video/cnbc-22844419/smartphone-smackdown-24039968
WSJ: Google Searches for Mobile-App Experts
http://online.wsj.com/article/SB10001424052748703554204576112723686094898.html
NYT: Moonlighting Within Microsoft, in Pursuit of New Apps
http://www.nytimes.com/2011/02/27/business/27novel.html?_r=2&partner=rss&emc=rss
It’s an App, App, App World: Are You Ready to Add Mobile Apps to Your Plan?
http://www.fastcompany.com/1698653/it-s-an-app-app-app-world-are-you-ready-to-add-mobile-apps-to-your-plan
App Mania: For teens, mobile apps have become part of life
http://www.guampdn.com/article/20110124/LIFESTYLE/101240319
App Store Beats iTunes to 10 Billion Downloads by 6 Years
http://gigaom.com/apple/app-store-beats-itunes-to-10-billion-downloads-by-6-years/
Are You Up for a Half-Hour TV Show About Mobile Apps?
http://mashable.com/2011/01/04/the-mo-show/
It’s A Mad, Mad, Mad, Mad, Mad App World
http://techcrunch.com/2010/12/24/its-a-mad-mad-mad-mad-mad-app-world/
Comparison of the growing trend of "mobile apps" vs. "social networks" using Google Trends:
"mobile apps"
http://www.google.com/trends?q=mobile+apps
"social networking"
http://www.google.com/trends?q=social+networking&ctab=0&geo=all&date=all&sort=0
"Katy Perry"
http://www.google.com/search?sourceid=chrome&ie=UTF-8&q=katy+perry
TPIV.OB, COMPANY I HAVE FOLLOWED FOR YEARS, BROKE OUT YESTERDAY FINISHING DAY AT .29 UP .06 ON VOL 5X AVG.
TPIV...this url should take you to an article on TAPIMMUNE that appeared in the March issue of Pharma and describes TAP's novel approach to their cancer vaccine...just click the link to site and then click the first article in the row...damn interesting stuff and I think it's gaining attn as TPIV vol last 3 days was almost half a million shares plus today's over 100,000 now clearly knocks out any recent vol activity and adds confirmation to the breakout as does the ferrari chart---and that kind of chart I have learned thru the years can just keep on giving....
http://www.tapimmune.com/news/media/
HERE IS A 6MO CHART OF TPIV-NOTE THE MULTI MONTH RANGE BOUND TRADING--THIS IS A FORMATION I CALL THE 'FERRARI' FORMATION BECAUSE YEAR IN AND YEAR OUT THIS PATTERN---MULTI MONTHS TRAPPED IN A TIGHT TRADING RANGE AND THEN A BREAKOUT---HAS MADE ME MORE MONEY FASTER THAN ANY OTHER TYPE OF PLAY, PROFILE, CHART, SET OF NUMBERS...NOTHING EQUALS WHAT THIS TYPE OF BREAKOUT CAN DELIVER IN TERMS OF PRICE MULTIPLES IN A SHORT PERIOD OF TIME. I HAVE BEEN TAKING THIS FERRARI FORMATION TO THE BANK FOR YEARS NOW---->>>>
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=TPIV&insttype=&freq=1&show=&time=7
ENSV .71...3/29--->WITH THE YEAR'S NUMBERS NOW IN PLUS THE FORECAST FOR 2011 PLUS THEIR EXPANSION IN BOTH MORE EQUIP AND GEOGRAPHIC AREAS THERE IS NO QUESTION IN MY MIND THAT WE HAVE A BONA FIDE UNDISCOVERED 5 STAR PLAY HERE-YOU HEARD IT HERE FIRST. I WILL STAKE MY REP ON THIS COMPANY'S PERFORMANCE FOR THIS FY AND I PREDICT A PRICE AT YEAR END IN THE $4-$5.00 RANGE. 19M SHARES.
ENSV.pk...for those who can recognize the rapid increase in the velocity of the numbers in this company including a rapidly growing bottom line combined with a singular opportunity to get in on the bottom price of a driller that is getting bigger and more profitable by the MONTH look at ENSV's year end today.
If you have the patience I think you could see this at 1.50-2.00 by end of May. If it gets recognized as a baby frac/driller play in the hot areas like the Marcellus shale, east Wyoming and a growing presence in the Bakken along with add'l geographic expansion in certain Rocky Mtn areas then the price could get caught up in an oil/gas resurgence in N America that may in time shift the balance of power in oil/gas reserves thru out the world. Then the price could go higher....MUCH HIGHER BY YEAR END. You heard it here first. See my prior posts. Price very low rel to present value and even lower looking ahead at the numbers for the next 6-9 mo. gpg
Well-Site Service Provider ENSERVCO Reports Fourth Quarter Financial Results; Revenue Increases 61% to $6.0 Million, Adjusted EBITDA Improves to $1.1 Million
marketwire
Press Release Source: ENSERVCO On Monday March 28, 2011, 7:00 am EDT
COLORADO SPRINGS, CO--(Marketwire - 03/28/11) - ENSERVCO Corporation (Pinksheets:ENSV - News) (Pinksheets:ENSV - News) a provider of well-site services to the domestic onshore oil and gas industry, today reported financial results for the fourth quarter and fiscal year ended December 31, 2010.
Fourth quarter revenue advanced 61% to $6.0 million from $3.7 million in the 2009 fourth quarter. Adjusted EBITDA* increased to $1.1 million versus negative $10,000 in the 2009 fourth quarter. Management said the growth in revenue and adjusted EBITDA was attributable to strong seasonal demand for ENSERVCO's fluid heating services, the positive impact of the Company's geographic expansion and a rebound in domestic onshore drilling activity.
ENSERVCO reduced its fourth quarter operating loss to $41,000 from $1.0 million in the 2009 fourth quarter. The Company achieved a positive bottom-line swing of $2.9 million, reducing its net loss to $163,000, or $0.01 per diluted share on 21,779,000 weighted average shares outstanding, versus a net loss of $3.0 million, or $0.21 per diluted share on 14,519,000 weighted average shares outstanding, in the fourth quarter of 2009.
Revenue for the full 2010 fiscal year increased 21% to $18.6 million from $15.4 million in 2009. Adjusted EBITDA* increased 388% to $2.0 million from $414,000 during the prior year. Loss from operations declined to $2.3 million from $4.0 million in 2009. Full-year net loss declined to $1.8 million, or $0.10 per diluted share on 17,642,000 weighted average shares outstanding, from $5.9 million, or $0.41 per diluted share on 14,519,000 weighted average shares outstanding, in 2009.
"The results of our 2010 expansion into the Northeast United States exceeded our expectations," said Mike Herman, chairman and chief executive officer. "We initiated operations in the Marcellus Shale region during the first quarter of 2010 to address the needs of a large existing customer. By the fourth quarter, we were serving 12 major exploration and production companies in the region. We now have a strong foothold in what has become one of North America's most active natural gas basins, and we are currently working to further expand our customer base and add services that will be counter seasonal to our heating operations."
"We also are encouraged by the progress we made in several of our core markets," Herman added. "In recent months, we have added several new customers in the Rocky Mountain region, where we anticipate we could see meaningful long-term growth. We believe our success at building market share in a competitive environment reflects the strength of our equipment portfolio and our reputation for outstanding customer service.
"Going forward, geographic expansion will remain one of our primary growth strategies. We are aggressively expanding our current operations in the Niobrara shale in eastern Wyoming, where state lease sales are commanding record valuations and there is intense competition among producers that are vying to drill in the formation. In addition, we continue to pursue opportunities in the active Bakken formation in North Dakota.
"Perhaps our most significant challenge in recent months is that customer demand has outstripped the availability of our well-site service equipment. Where possible, we have redeployed assets and personnel to more optimal locations, but we are also working to accelerate the construction of new trucks and equipment. Finally, we are actively evaluating opportunities to add new services that could augment our revenue stream and help mitigate the seasonality of our fluid heating business."
Rick Kasch, chief financial officer, said the Company is off to a strong start to fiscal 2011. "January represented a new monthly record for revenue, and given the favorable environment for the domestic oil and gas industry and our aggressive growth strategy, we are optimistic we will see continued improvements in our financial performance throughout 2011."
About ENSERVCO
Through its two operating subsidiaries, Heat Waves Hot Oil Service and Dillco Fluid Service, ENSERVCO has emerged as one of the energy service industry's leading providers of hot oiling, acidizing, frac heating and fluid management services. The Company owns and operates a fleet of more than 200 specialized trucks, trailers, frac tanks and related well-site equipment. ENSERVCO operates in Colorado, Kansas, New Mexico, Oklahoma, Pennsylvania, Texas, Utah and Wyoming. ENSERVCO became a public company in July 2010 when it merged with Aspen Exploration Corporation, which is now doing business under the trade name ENSERVCO Corporation. Additional information about the Company is available at www.enservco.com.
ENSV .71-
ENSV .68 big progress and prospects detailed
Issued: 21,882,466 shares
Results; Revenue Increases 61% to $6.0 Million, Adjusted EBITDA Improves to $1.1 Million
Mar 28, 2011 6:00:00 AM
COLORADO SPRINGS, CO -- (MARKET WIRE) -- 03/28/11 -- ENSERVCO Corporation(OTCQB: ENSV) (PINKSHEETS: ENSV) a provider of well-site services to the domestic onshore oil and gas industry, today reported financial results for the fourth quarter and fiscal year ended December 31, 2010.
Fourth quarter revenue advanced 61% to $6.0 million from $3.7 million in the 2009 fourth quarter. Adjusted EBITDA* increased to $1.1 million versus negative $10,000 in the 2009 fourth quarter. Management said the growth in revenue and adjusted EBITDA was attributable to strong seasonal demand for ENSERVCO's fluid heating services, the positive impact of the Company's geographic expansion and a rebound in domestic onshore drilling activity.
ENSERVCO reduced its fourth quarter operating loss to $41,000 from $1.0 million in the 2009 fourth quarter. The Company achieved a positive bottom-line swing of $2.9 million, reducing its net loss to $163,000, or $0.01 per diluted share on 21,779,000 weighted average shares outstanding, versus a net loss of $3.0 million, or $0.21 per diluted share on 14,519,000 weighted average shares outstanding, in the fourth quarter of 2009.
Revenue for the full 2010 fiscal year increased 21% to $18.6 million from $15.4 million in 2009. Adjusted EBITDA* increased 388% to $2.0 million from $414,000 during the prior year. Loss from operations declined to $2.3 million from $4.0 million in 2009. Full-year net loss declined to $1.8 million, or $0.10 per diluted share on 17,642,000 weighted average shares outstanding, from $5.9 million, or $0.41 per diluted share on 14,519,000 weighted average shares outstanding, in 2009.
"The results of our 2010 expansion into the Northeast United States exceeded our expectations," said Mike Herman, chairman and chief executive officer. "We initiated operations in the Marcellus Shale region during the first quarter of 2010 to address the needs of a large existing customer. By the fourth quarter, we were serving 12 major exploration and production companies in the region. We now have a strong foothold in what has become one of North America's most active natural gas basins, and we are currently working to further expand our customer base and add services that will be counter seasonal to our heating operations."
"We also are encouraged by the progress we made in several of our core markets," Herman added. "In recent months, we have added several new customers in the Rocky Mountain region, where we anticipate we could see meaningful long-term growth. We believe our success at building market share in a competitive environment reflects the strength of our equipment portfolio and our reputation for outstanding customer service.
"Going forward, geographic expansion will remain one of our primary growth strategies. We are aggressively expanding our current operations in the Niobrara shale in eastern Wyoming, where state lease sales are commanding record valuations and there is intense competition among producers that are vying to drill in the formation. In addition, we continue to pursue opportunities in the active Bakken formation in North Dakota.
"Perhaps our most significant challenge in recent months is that customer demand has outstripped the availability of our well-site service equipment. Where possible, we have redeployed assets and personnel to more optimal locations, but we are also working to accelerate the construction of new trucks and equipment. Finally, we are actively evaluating opportunities to add new services that could augment our revenue stream and help mitigate the seasonality of our fluid heating business."
Rick Kasch, chief financial officer, said the Company is off to a strong start to fiscal 2011. "January represented a new monthly record for revenue, and given the favorable environment for the domestic oil and gas industry and our aggressive growth strategy, we are optimistic we will see continued improvements in our financial performance throughout 2011."
ENSV .71-
ENSV.ob $.70......there are very few oil service companies working the Marcellus shale elephant and the emerging Bakken elephant ref to share gas and ENSV, formerly Aspen Exploration, is one of them. They are now expanding their fleet to handle the burgeoning demand esp for their fracking scvs offered as part of their ttl service to the well operators. Stock is at .70, they are turning their numbers around, and as a high risk potential very high reward play they are as good a shot as anything out here. 21m shares out....
From CEO-
"On the operational front, our growth program is proceeding on plan. Our
first full winter in the Marcellus Shale is keeping our Heat Waves subsidiary
very busy, and we are working to expand capacity in the region to address
strong customer demand. We are encouraged by our recent progress and our
prospects for growth in fiscal 2011."
About ENSERVCO
Through its two operating subsidiaries, Heat Waves Hot Oil Service and
Dillco Fluid Service, ENSERVCO has emerged as one of the energy service
industry's leading providers of hot oiling, acidizing and frac heating
services. The Company owns and operates a fleet of more than 200 specialized
trucks, trailers, frac tanks and related well-site equipment. ENSERVCO
operates in Colorado, Kansas, New Mexico, Oklahoma, Pennsylvania, Texas, Utah
and Wyoming. ENSERVCO became a public company in July 2010 when it merged
with Aspen Exploration Corporation, which is now doing business under the
trade name ENSERVCO Corporation. Additional information about the Company is
available at www.enservco.com.
ENSV .71-
ENSV-they have expanded to Bakken since this last 10q came out and have beefed up their fleet of scv units....
$ENSV .70-from last 10q-We believe our operations in the Marcellus Shale region will continue to positively impact revenues in future months....
Just can't find many suppliers of fracturing scvs that are public and microcaps.
db...company is current with all filings, DTC eligible...maybe you should try a broker that lets you make your own decisions. The reason, no matter what they may say, that they are not trading it yet unless you call-maybe- is this--vol for last 15 weeks-does not pay for them to file for trading it...not yet. Only other remote possibility is that they took over a shell to come public but that was almost a year ago and as stated all filings are current. Companies have been coming to mkt via shell corps since I have been doing this. Whatever they may say Fidelity takes the orders and they are the big gorilla. If you want the stock you can buy it. Etrade trades it.
03/16/11 0.7500 0.9100 0.7500 0.9000 +0.2500 12,700
03/11/11 0.9100 0.9100 0.5500 0.6500 -0.2500 15,670
03/03/11 0.2500 1.0000 0.2500 0.9000 +0.1900 118,175
02/23/11 0.7100 0.7100 0.7100 0.7100 -0.1400 100
02/17/11 0.2500 0.8500 0.2000 0.8500 +0.3500 100
02/01/11 0.5000 0.5000 0.4990 0.5000 +0.0010 8,600
01/27/11 0.8500 0.9000 0.2000 0.4990 -0.4010 32,202
01/07/11 0.6500 0.9000 0.6500 0.9000 +0.3500 3,230
12/30/10 0.5500 0.5500 0.5500 0.5500 -0.4600 6,300
12/03/10 0.7500 1.0100 0.7500 1.0100 +0.2600 400
11/19/10 0.7500 0.7500 0.7500 0.7500 -0.2600 4,000
11/11/10 0.4500 1.0100 0.4000 1.0100 +0.5100 52,700
11/05/10 0.4500 0.8000 0.2000 0.5000 +0.2000 107,665
10/15/10 0.3900 0.4000 0.2500 0.3000 -0.1300 31,750
10/08/10 0.4000 0.5000 0.4000 0.4300 +0.0400 4,500
10/01/10 0.2500 0.5100 0.2500 0.3900 -0.2100 26,166
09/22/10 0.6000 0.6000 0.6000 0.6000 +0.0000 3,800
tried in my 401k.. merryl lynch.. "Orders for this security are currently prohibited. [CI01] (RES_SPD-RET)
"
TDAmer has the largest restricted list of all the brokers. If the stock does not have enough vol for them they will say their 'algorithms' preclude them from trading the stock....which is pure bs. I have been w/them for 15 years-same 15 years I have been with Fidelity and every single trade TDAmer turned down Fidelity accepted. You can override the TDAmer fiat by calling them. I only stay with them for the perks I get. Whatever way you want to do it you are going to want at least SOME of this stock as once it begins trading a bit more and the spread tightens the word will go out about this company and their search engine for apps. Look into the background of the CEO and the rest of the team and the advisory board. This is no 'small' enterprise in terms of its backers. My opinion only would have been to wait, develop a bit more, then straight IPO but CEO was caught in a crossfire some time back by NOT being public so he wanted to come out this way. WHATEVER the way it came to market and whatever broker buys or sells it is all moot. The only thing to recognize is what is right here in front of you no matter how it got here.
can't even buy via TDA, "Opening transactions for this security are not accepted."
very interesting.. added to watch..thanks gpg
MIMV.OB-$.90.....pay the wide spread...it's a pittance compared to where this is going....search engine for apps-every one and every thing worldwide will have its own app----
03/15/11Mobile App Search Company, Mimvi, Adds Satish Gupta to Advisory Board
# Mimvi Positioned for Mobile App Internet Expansion Into ChinaMarketwire(Tue, Mar 8)
# Mimvi Signs Deal With Intertrust to Develop Mobile & Search TechnologyGlobeNewswire(Wed, Dec 8)
# Mobile App Co., Mimvi, Launches the World's First Discovery Engine for Health AppsGlobeNewswire(Thu, Dec 2)
# Mimvi Launches Mobile App Search Engines for Apple iPhone, Google Android and BlackBerry SmartphonesGlobeNewswire(Thu, Nov 18)
# Mobile App Company, Mimvi, Launches Largest Recommendation Engine for Mobile GamingGlobeNewswire(Thu, Nov 11)
# Daiwa Quantum Capital, Led by the Former CEO of Sony, Joins Advisory Board of Mobile App Search Company, Mimvi, Inc.GlobeNewswire(Tue, Nov 9)
* Original MySpace Investor Joins Mimvi's Advisory BoardGlobeNewswire (Thu, Nov 4)
* NBT Research, LLC Issues New Research Report on Mimvi, Inc.GlobeNewswire (Thu, Nov 4)
* Mimvi, Inc. Announces Patent Filing for "Intelligent" Mobile App Search and Recommendation TechnologyGlobeNewswire (Wed, Oct 20)
Thursday, September 16, 2010
* Mimvi Announces the Availability of a New Video Interview With Company CEO and Chief Visionary Officer, Kasian FranksGlobeNewswire (Thu, Sep 16)
===========
http://www.mimvi.com/health
http://www.mimvi.com/games
We also have separate vertical engines for iPhone, Android and Blackberry:
http://www.mimvi.com/apple
http://www.mimvi.com/android
http://www.mimvi.com/blackberry
Here are some links that you might find interesting:
Forrester: The Mobile App Internet: Making Sense Of The 2011 Mobile Hysteria
http://blogs.forrester.com/john_mccarthy/11-02-28-mobile_app_internet_making_sense_of_the_2011_mobile_hysteria
Google CEO: Mobile Growing Faster Than “All Our Predictions” [VIDEO]
http://mashable.com/2011/02/28/schmidt-mobile-growth/
Google goes to war with Apple over mobile apps
http://www.theinquirer.net/inquirer/news/2012494/google-goes-war-apple-mobile-apps
SF Cron: "Mobile is the biggest platform war ever,"
http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2011/02/21/BUI01HOUH6.DTL&type=business
“The trend is crazy, it’s unbelievably fast. Faster than when Netscape took off.”
http://www.troymedia.com/2011/02/25/alberta-companies-creating-bleeding-edge-mobile-apps/
Bill Gates: Mobile Devices to Revolutionize Health Care
"without this mobile phone app these people would have died" Now how do they find this mobile phone app? This correlates directly with the mobile health app search vertical Mimvi is releasing.
http://www.mobiledia.com/news/76764.html
FastCompany: 500 Million People to Use Mobile Health Apps [Alone] by 2015 (bigger than Facebook)
http://www.fastcompany.com/1701769/mhealth-summit-wraps-reveals-booming-industry
Mimvi described as the "Google" for mobile apps
http://www.theipadguide.com/content/top-five-places-find-best-ipad-applications/7176729
"Mimvi is Like Google For Smartphone Apps and Games"
http://www.guidingtech.com/mobiles/mimvi-mobile-phone-apps-search/
seekingalpha: Huge Tech Growth Expected from Apps
http://seekingalpha.com/article/253865-huge-tech-growth-expected-from-apps
NYT: "products being built first as mobile apps, with the Web site as second priority"
http://www.nytimes.com/2010/11/11/technology/11photo.html
Sir Martin Sorrell says mobile apps are 'holy grail' for advertisers
http://www.telegraph.co.uk/finance/newsbysector/mediatechnologyandtelecoms/media/8327348/Sir-Martin-Sorrell-says-mobile-apps-are-holy-grail-for-advertisers.html
MarketWatch: Top 5 reasons to invest in the app eco-system
"Your mom, your tennis partner, your grocer, your career mentor and the used car salesman you met with your sister-in-law all have a new Android or iPhone and they ask you about apps everytime you see them." The app builders are important just like the web builders of the 90's, but it was the web search engines that became the most valuable
http://blogs.marketwatch.com/cody/2011/02/18/top-5-reasons-you-know-the-app-revolution-is-real
ERICSSON: Mobile apps will transform business and industries
http://www.4-traders.com/ERICSSON-A-445400/news/ERICSSON-A-Mobile-apps-will-transform-business-and-industries-13561196/
Mobile World Congress: Apps become key driver of smartphone market
http://www.v3.co.uk/v3/news/2274787/mwc-applications-smartphones
Mary Meeker: Mobile Internet Will Soon Overtake Fixed Internet
http://gigaom.com/2010/04/12/mary-meeker-mobile-internet-will-soon-overtake-fixed-internet/
Smartphones Outsell PCs
http://www.readwriteweb.com/archives/smartphones_outsell_pcs.php
Mobile apps use second only to messaging
http://www.intomobile.com/2011/02/15/mobile-apps-research
CNBC Video: Smartphone Smackdown - Based on the Apps
http://finance.yahoo.com/video/cnbc-22844419/smartphone-smackdown-24039968
WSJ: Google Searches for Mobile-App Experts
http://online.wsj.com/article/SB10001424052748703554204576112723686094898.html
NYT: Moonlighting Within Microsoft, in Pursuit of New Apps
http://www.nytimes.com/2011/02/27/business/27novel.html?_r=2&partner=rss&emc=rss
It’s an App, App, App World: Are You Ready to Add Mobile Apps to Your Plan?
http://www.fastcompany.com/1698653/it-s-an-app-app-app-world-are-you-ready-to-add-mobile-apps-to-your-plan
App Mania: For teens, mobile apps have become part of life
http://www.guampdn.com/article/20110124/LIFESTYLE/101240319
App Store Beats iTunes to 10 Billion Downloads by 6 Years
http://gigaom.com/apple/app-store-beats-itunes-to-10-billion-downloads-by-6-years/
Are You Up for a Half-Hour TV Show About Mobile Apps?
http://mashable.com/2011/01/04/the-mo-show/
It’s A Mad, Mad, Mad, Mad, Mad App World
http://techcrunch.com/2010/12/24/its-a-mad-mad-mad-mad-mad-app-world/
Comparison of the growing trend of "mobile apps" vs. "social networks" using Google Trends:
"mobile apps"
http://www.google.com/trends?q=mobile+apps
"social networking"
http://www.google.com/trends?q=social+networking&ctab=0&geo=all&date=all&sort=0
"Katy Perry"
http://www.google.com/search?sourceid=chrome&ie=UTF-8&q=katy+perry
update on my prior post.. opxa up huge
GFS.V...$9.20....this is not a microcap but the numbers are astonishing and show no signs of slowing so I have bot it. Gasfrac....going to replace hydraulic fracking to get more oil out...in its infancy....very near 52wh...GSFVF.pk....TMC
Here is another view on WEBM from Seeking Aplha author--
WEBM...here is one way to play Facebook--
How Investors Can Finally Cash In on the $41 Billion Facebook Empire
By Alexander Moschina
Without question, Facebook is one of the biggest stories of the last decade. Its founder and CEO, Mark Zuckerberg, was just named Time Magazine’s “Person of the Year” for 2010. Yet only he and a few people got rich off the $41 billion social networking site.
Until now, that is.
No, the company isn’t going public. Even if it did, its IPO would be astronomical. But there is a way to cash in on Facebook’s massive success. For roughly $1 per share…
Facebook news site AllFacebook.com recently launched a new subscription-based service – the AllFacebook Services Directory. It’s an online marketplace, where businesses can advertise Facebook-related marketing, software and other services.
The site already attracts more than a million unique visitors per month. And the tiny company behind it has a market cap of $26.7 million. News of the launch sent its shares soaring more than 50%. But it’s just a preview of things to come…
Facebook Ad Revenue Set to Blast Past AOL
When it comes to monetizing the web, New York City’s WebMediaBrands (Nasdaq: WEBM) has been at the forefront for over a decade. It manages a network of professional blogs, career sites and newsletters.
But today, the company has its sights on Facebook. Particularly the $800 million in ad revenue it raked in last year…
Analysts predict that Facebook will soon reach $1.4 billion in recurring ad revenue, crushing web veterans like AOL (NYSE: AOL). And as Facebook’s strength as an ad medium grows, so too will demand for WebMediaBrands’ new service…
WebMediaBrands Gets In on the Ground Floor of a Rapidly-Growing Market
Now that the social networking site has reached 500 million users, it’s attracting some major brands. But did you know that more than half of its ad revenue still comes from small businesses? And the common denominator here is that they need help marketing in the new adspace…
That’s where online ad firms like WebMediaBrands come in. They make a living advertising on social media sites. Unfortunately, though, potential clients have a hard time finding them on the open web.
WebMediaBrands’ AllFacebook Service Directory is like the Yellow Pages for Facebook advertising. A monthly subscription fee ensures that the businesses listed are legitimate. And for WebMediaBrands, this creates a significant repeat revenue stream. Not to mention it gains access to a young market currently worth more than $400 million…
The directory is a game-changer for the company and the service’s success will likely lead to others like it. Its site SocialTimes.com could easily host a directory for companies that market on Twitter, YouTube and other sites.
Over the coming years, WebMediaBrands will continue to unlock the web’s profit potential. And as social networking evolves, the company will expand its business as it creates even more revenue streams.
WEBM off to good start this am....up .09 to 1.20...I think you pay the freight now for a Facebook play (like STVI which I rec'd last Aug at .20 and again in Oct...now 1.31 on fantastic run from .20 last Thurs) or you may end up paying more freight going forward....
nice examples of ones that 'have' run.. any ideas on up and coming ones with potential?
i like cigx/opxa/axk/opxa/ssn/cbmx for early 2011 runs fwiw
KEY #1 TO BULLISH CASE FOR MICROCAPS AS WE TURN THE YEAR VSCP, KOOL, API, RPC, WEBM, STVI and many, many others with very large % gains...this is what you want to see as tax selling draws to a close and you are turning the year....good bullish omen for micros.....DARA, RPRX, MSHL, BASI....all of these were rippin' today...and the overall advance/decline line showing strength as well. THERE WERE A WHOLE HOST OF GAINERS SPREAD ALL THRU THE EXCHANGES.
KEY#2 IS THE ADVANCE/DECLINE LINE BY EXCHANGE
NYSE today had 1,261,724,200 advancing shares
and 777,101,900 declining shares
NASDAQ 636,984,800 advancing shares
and 439,066,400 declining
AMEX had 316,979,500 advancing shares
and 230,079,600 declining
OTCBB had 675,210,300 shares advancing
and only 278,465,800 declining
KEY #3 THAT THE MICRO MOVE UNDERWAY IS HERE TO STAY FOR AT LEAST THE NEXT 4-6 MONTHS-NEW HIGHS OVER NEW LOWS BY EXCHANGE---
NYSE 148 new highs, 8 new lows
NASDAQ 175 new highs, 6 new lows
AMEX 104 new highs, 16 new ,lows
OTCBB 33 new highs, 27 new lows
I have been saying form some time now, but not here yet, that the case is building for the microcaps to undergo an extended run akin to the 2000 run that had about an 11mo GO before we internet tanked. This is long overdue and I can tell you this is what I do when I believe one of these runs is coming into play---I fully commit all my capital, I keep the pedal to the metal on the push, I play pre 9.30 and post 4p, I pay attn to the mkts as they circle the globe to see what major sectors are taking part in the play or who may next...I just ram jam the mm's, my various brokers, and keep the phone going almost all the time.
Reason for the above is simple...when you catch a microcap run right before liftoff you can accumulate a great deal of stock at still depressed prices and as those issue catch fire you will be distributing while others are accumulating...so I like to try and spot a bull early down here, go after my money stocks, get them in play right off the bat...and see if there are rewards to reap.
So far so good.
==========================================
API....Advanced Photonix on the AMEX..has run a beautiful chart from the .50 level earlier this year--
http://stockcharts.com/h-sc/ui?s=api
Key to this play, or at least one o the keys, is their growing LED exposure. Oppenheimer and Caris have been raising their targets on LED stock plays incl CREE. Just today Caris raised their Cree target to $78 from $55. That is one BIG raise.
Well, API is in this game as well as advanced optoelectronics---including some golden works from the past that meant tens of millions of $$$ in profits for investors who caught on early--from a recent contract win---
The new design wins are for 100 Gb/S long haul communications in dense wavelength division multiplexing (DWDM) systems that utilize DP-QPSK and DP-BPSK modulation
That's right-DWDM---do you remember?? If you do climb into the belly of this stock and learn it inside out---fun could just be beginning and altho we are up .19 to 1.76 today that again could be just the start...
When you are digging don't miss these--
Thursday, November 11, 2010
* Advanced Photonix, Inc. Wins Another Terahertz Contract to Help the Department of Homeland Security Detect Concealed ThreatsPR Newswire (Thu, Nov 11)
Friday, November 5, 2010
* Advanced Photonix, Inc. Announces Development Agreement for Next Generation T-Ray® 4000 SystemPR Newswire (Fri, Nov 5)
Then that was one fine call aquaspin. Anything else you may like with similar characteristics would certainly be welcome.
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
68
|
Created
|
11/05/10
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |